

1.1 **Board of Pharmacy**1.2 **Proposed Permanent Rules for Pharmacy Practice**1.3 **6800.0100 DEFINITIONS.**1.4 [For text of subps 1 to 1b, see M.R.]

1.5 Subp. 1c. **Central service pharmacy.** "Central service pharmacy" means a  
1.6 pharmacy that may provide dispensing functions, drug utilization review (DUR),  
1.7 packaging, labeling, or delivery of a filled prescription ~~product to~~ for another pharmacy  
1.8 for the purpose of filling a prescription.

1.9 Subp. 2. ~~Community/retail~~ **Community/outpatient pharmacy.** "~~Community/retail~~  
1.10 Community/outpatient pharmacy" means an established place in which prescriptions,  
1.11 drugs, medicines, chemicals, and poisons are prepared, compounded, dispensed, vended,  
1.12 distributed, or sold to or for the use of nonhospitalized patients and from which related  
1.13 pharmaceutical care services are provided. Practitioners, as defined in Minnesota Statutes,  
1.14 section 151.01, subdivision 23, dispensing prescription drugs to their own patients in  
1.15 accordance with parts 6800.9950 to 6800.9954 are not included within this definition.

1.16 Subp. 2a. [See repealer.]1.17 [For text of subps 2b to 3a, see M.R.]

1.18 Subp. 4. **Long-term care pharmacy.** "Long-term care pharmacy" means  
1.19 an established place, whether or not in conjunction with a hospital pharmacy or a  
1.20 ~~community/retail~~ community/outpatient pharmacy, in which prescriptions, drugs,  
1.21 medicines, chemicals, or poisons are prepared, compounded, dispensed, vended,  
1.22 distributed, or sold on a regular and recurring basis to or for the use of residents of a  
1.23 licensed nursing home, boarding care home, assisted living facility, or supervised living  
1.24 facility and from which related pharmaceutical care services are delivered.

1.25 [For text of subps 4a and 5, see M.R.]

2.1 Subp. 6. ~~Parenteral-enteral/home~~ Home health care pharmacy.

2.2 ~~"Parenteral-enteral/home~~ "Home health care pharmacy" means an established place,  
2.3 whether or not in conjunction with a hospital pharmacy, long-term care pharmacy, or a  
2.4 ~~community/retail~~ community/outpatient pharmacy, in which parenteral or enteral drugs  
2.5 or medicines are prepared, compounded, and dispensed for the use of nonhospitalized  
2.6 patients and from which related pharmaceutical care services are provided.

2.7 [For text of subps 7 to 10, see M.R.]

2.8 Subp. 11. **Prescription drug order.** "Prescription drug order" means a lawful  
2.9 written, oral, or electronic order of a practitioner for a drug for a specific patient. A  
2.10 prescription drug order must contain the information specified in this chapter and in  
2.11 Minnesota Statutes, section 151.01, subdivision 16.

2.12 Subp. 11a. **Prescription.** "Prescription" means a prescription drug order that is  
2.13 written or printed on paper, an oral order reduced to writing by a pharmacist, or an  
2.14 electronic order. To be valid a prescription must be issued for an individual patient  
2.15 by a practitioner within the scope and usual course of the practitioner's practice, and  
2.16 must contain the date of issue, name and address of the patient, name and quantity of  
2.17 the drug prescribed, directions for use, the name and address of the practitioner, and  
2.18 a telephone number at which the practitioner can be reached. A prescription written or  
2.19 printed on paper that is given to the patient or an agent of the patient, or transmitted  
2.20 facsimile-to-facsimile must contain the practitioner's manual signature. An electronic  
2.21 prescription must contain the practitioner's electronic signature.

2.22 Subp. 11b. **Chart order.** "Chart order" means a prescription drug order for a  
2.23 drug that is to be dispensed by a pharmacist, or by a pharmacist-intern under the direct  
2.24 supervision of a pharmacist, and administered by an authorized person only during the  
2.25 patient's stay in a hospital or long-term care facility. The chart order shall contain the  
2.26 name of the patient, the drug ordered, and any directions as the practitioner may prescribe

3.1 concerning strength, dosage, frequency, and route of administration. The manual or  
3.2 electronic signature of the practitioner must be affixed to the chart order at the time it is  
3.3 written or at a later date in the case of verbal chart orders.

3.4 [For text of subps 12 and 13, see M.R.]

3.5 Subp. 14. **Nonsterile product compounding.** "Nonsterile product compounding"  
3.6 means the preparation, mixing, assembling, packaging, and labeling of a nonsterile drug  
3.7 product, according to United States Pharmacopeia Chapter 795.

3.8 Subp. 15. **Sterile product compounding.** "Sterile product compounding" means the  
3.9 preparation, mixing, assembling, packaging, and labeling of a drug product that achieves  
3.10 sterility, according to United States Pharmacopeia Chapter 797.

3.11 Subp. 16. **Limited service pharmacy.** "Limited service pharmacy" means a  
3.12 pharmacy to which the board may assign a restricted license to perform a narrow range  
3.13 of the activities that constitute the practice of pharmacy.

3.14 Subp. 17. **Unique identifier.** "Unique identifier" means a manual signature or  
3.15 initials, a biometric identifier, or a board-approved electronic means of identifying only  
3.16 one individual.

3.17 **6800.0300 PHARMACY LICENSE AND FEE REQUIRED.**

3.18 No person or persons shall conduct a pharmacy in or outside of Minnesota that  
3.19 dispenses ~~medications~~ legend drugs for Minnesota residents and mails, ships, or delivers  
3.20 the ~~prescription medications~~ legend drugs into this state unless the pharmacy is licensed by  
3.21 the Board of Pharmacy. A fee set by the board and indicated in part ~~6800.0400~~ established  
3.22 in Minnesota Statutes, chapter 151, shall be charged for a license.

3.23 A completed new pharmacy license application together with a blueprint of the  
3.24 proposed pharmacy showing size, layout, and security and a check for the proper fee must  
3.25 be received in the board office at least 60 days prior to the proposed opening date of  
3.26 the pharmacy.

4.1 An application for a pharmacy license which has not been completed within 12  
4.2 months of the date on which the board received the application is no longer valid.

4.3 **6800.0350 LICENSE CATEGORIES.**

4.4 A pharmacy must be licensed in one or more of the following categories:

4.5 A. ~~community/retail~~ community/outpatient;

4.6 B. hospital;

4.7 C. ~~parenteral-enteral/home~~ home health care;

4.8 D. long-term care;

4.9 E. nuclear; and

4.10 F. central service;

4.11 G. nonsterile product compounding;

4.12 H. sterile product compounding;

4.13 I. veterinary; and

4.14 J. limited service.

4.15 Licensing of a pharmacy in more than one category shall not result in an increase  
4.16 in the license fee.

4.17 No pharmacy may engage in providing products or services in categories for which it  
4.18 is not licensed. A pharmacy must designate its category or categories on license renewal  
4.19 or application for an initial license. Effective January 3, 2012, the license issued by  
4.20 the board shall list each license category for which the pharmacy has received board  
4.21 approval. A pharmacy must receive board approval before providing services in a license  
4.22 category not listed on its license. A pharmacy must notify the board if the pharmacy no  
4.23 longer provides services in a license category. The board shall issue a revised license if it  
4.24 approves a pharmacy's request to provide services in additional license categories or if a

5.1 pharmacy no longer provides services in one or more license categories. No additional fee  
 5.2 shall be required for issuance of a revised license.

5.3 The board may establish special conditions for licensure, appropriate to the situation,  
 5.4 before approving a license application for a pharmacy with a limited service license  
 5.5 category. Such pharmacies must also apply for and receive any necessary variances,  
 5.6 according to part 6800.9900, before an application for licensure is approved.

5.7 **6800.0400 ANNUAL LICENSE RENEWAL DATE AND FEES.**

5.8 Each pharmacy license shall expire on June 30 of each year and shall be renewed  
 5.9 annually by filing an application for license renewal, on or before June 1 of each year,  
 5.10 together with a fee of ~~\$165~~ established in Minnesota Statutes, chapter 151. Renewal  
 5.11 applications received on or after July 1 are subject to a late filing fee of an amount equal to  
 5.12 50 percent of the renewal fee in addition to the renewal fee.

5.13 **6800.0500 SEPARATE LICENSE REQUIRED.**

5.14 Subpart 1. Transfer of license restrictions. A separate license shall be required for  
 5.15 each pharmacy and is not transferable. The following shall be considered a transfer of  
 5.16 ownership requiring relicensure:

5.17 [For text of items A and B, see M.R.]

5.18 C. the change of ownership of 20 percent or more of the issued voting stock  
 5.19 of a corporation pharmacy since the issuance of the license or the last renewal; this does  
 5.20 not apply to any corporation the voting stock of which is actively traded on any securities  
 5.21 exchange or in any over-the-counter market; or

5.22 D. the change in ownership from one form to another: sole proprietor,  
 5.23 partnership, or corporation; ~~or.~~

5.24 E. ~~the addition, deletion, or change of categories of licensure.~~

6.1 Subp. 2. **Transfer of ownership.** For a transfer of ownership, the new owner must  
6.2 submit a completed pharmacy license application prior to the effective date of the transfer.  
6.3 Upon a transfer of ownership, the new owner can continue operation of the pharmacy  
6.4 under the license issued to the prior owner for 14 days after the effective date of the  
6.5 change of ownership or until the board issues a new license, whichever is earlier. After the  
6.6 14-day period, the license issued to the prior owner is void and must be surrendered to  
6.7 the director of the board.

6.8 **6800.0700 PHARMACY, SPACE, AND SECURITY.**

6.9 Subpart 1. **Minimum requirements.** No person shall be issued a license to conduct  
6.10 a pharmacy located in Minnesota unless the pharmacy:

6.11 [For text of items A to D, see M.R.]

6.12 E. in the case of a ~~community/retail~~ community/outpatient pharmacy, contains  
6.13 an area where consultation between the patient and the pharmacist may be conducted  
6.14 with ~~an a~~ a reasonable assurance of privacy. ~~Community/retail pharmacies in existence on~~  
6.15 ~~February 1, 1999, have until February 1, 2001, to comply with this item; and~~ All new and  
6.16 remodeled community/outpatient pharmacies must meet the standards of this subpart. A  
6.17 pharmacy licensed before January 1, 2011, must meet the standards within two years of  
6.18 that date, unless the pharmacy has an existing counseling area that is deemed by the board  
6.19 to provide a reasonable assurance of privacy. For pharmacies using partitions to create a  
6.20 consultation area in which the patient will typically remain standing, the partitions must  
6.21 be sound-dulling and at least seven feet high and 24 inches deep. The patient must be  
6.22 able to step into the partitioned area so that the partitions are on each side of the patient.  
6.23 Consultation areas without partitions may be approved if the board deems the consultation  
6.24 area will provide a reasonable assurance of privacy. Consultation areas must not contain  
6.25 any item for sale apart from the articles needed for counseling sessions. An accessible  
6.26 computer terminal for patient profile review and clinical documentation must be available.

7.1 Consultation areas must be accessible to the patient outside of the prescription dispensing  
7.2 area and open at all times when the pharmacy is open; and

7.3 [For text of item F, see M.R.]

7.4 [For text of subp 2, see M.R.]

7.5 **6800.0910 PATIENT ACCESS TO PHARMACIST.**

7.6 [For text of subp 1, see M.R.]

7.7 Subp. 2. **Description of procedure.** When dispensing a filled prescription for a  
7.8 patient, a pharmacist must consult with the patient or the patient's agent or caregiver and  
7.9 inquire about the patient's understanding of the use of the ~~medication~~ drug according to  
7.10 this part.

7.11 A. Upon receipt of a new prescription ~~or a new prescription drug order~~,  
7.12 following a review of the patient's record, a pharmacist shall personally initiate discussion  
7.13 of matters which in the professional judgment of the pharmacist will enhance or optimize  
7.14 drug therapy with each patient or the agent or caregiver of the patient. The discussion shall  
7.15 be in person, whenever applicable, may be supplemented with written material, and shall  
7.16 include appropriate elements of patient counseling. These elements include the following:

7.17 [For text of subitems (1) to (10), see M.R.]

7.18 B. The pharmacist must counsel the patient on a refilled prescription if deemed  
7.19 necessary according to the pharmacist's professional judgment. The consultation must be  
7.20 in person whenever applicable.

7.21 A pharmacist may vary or omit the patient information if, in the pharmacist's  
7.22 professional judgment, the variation or omission serves the best interest of the patient  
7.23 because of the particular individual circumstances involved. If there is any material  
7.24 variation from the minimal information required by this subpart in the information

8.1 provided or, if consultation is not provided, that fact and the circumstances involved shall  
8.2 be noted on the prescription, in the patient's records, or in a specially developed log.

8.3 Personal communication by the pharmacist is not required for inpatients of a hospital  
8.4 or other institution, such as a licensed nursing home, where other licensed health care  
8.5 professionals are authorized to administer the drugs, or where a patient or patient's agent  
8.6 or caregiver has expressed a desire not to receive the consultation. When a new filled  
8.7 prescription or a refilled prescription for which counseling is required is being mailed or  
8.8 delivered to the patient by common carrier or delivery services, the consultation must still  
8.9 be provided but may be accomplished by providing written information to the patient  
8.10 regarding the medication being dispensed and the availability of the pharmacist to answer  
8.11 questions, and through the provision of a toll-free phone number for long distance calls.

8.12 Nothing in this part shall prohibit pharmacists from charging for these services.

8.13 **~~6800.0950 SALE RESTRICTED TO LIMITED AREA UNDER~~**  
8.14 **~~SUPERVISION REQUIREMENT FOR A SUPERVISED PHARMACY AREA.~~**

8.15 The Board of Pharmacy shall refuse to grant a pharmacy license to any ~~pharmacy~~  
8.16 ~~or proposed pharmacy~~ existing or proposed facility or place of business unless there  
8.17 ~~is provided in the pharmacy a prescription department and a drug area which is used~~  
8.18 ~~exclusively for the display, sale, compounding, and dispensing of drugs, medicines,~~  
8.19 ~~chemicals, and poisons, and for the display and sale of other items used in the cure,~~  
8.20 ~~mitigation, treatment, or prevention of disease in humans or other animals.~~ facility  
8.21 or place of business has an area that meets the definition of and the requirements for a  
8.22 pharmacy according to this chapter. The pharmacy area must be under the supervision  
8.23 of a licensed pharmacist. The board may issue a pharmacy license for a limited service  
8.24 pharmacy according to part 6800.0350.

8.25 **6800.1010 CLOSING A PHARMACY.**

8.26 [For text of subp 1, see M.R.]



9.1 Subp. 2. **At time of closing.** Effective with the closing date, the pharmacist-in-charge  
9.2 shall:

9.3 A. return the pharmacy license to the board office, noting the closing date;

9.4 B. notify the board as to the disposition of the prescription files, ~~prescription~~  
9.5 legend drugs, insulin, hypodermic syringes and needles, contraceptive drugs and devices,  
9.6 chemicals, and nonprescription drugs;

9.7 [For text of items C to F, see M.R.]

9.8 Subp. 3. **Public notification.** A licensed pharmacy must provide the following  
9.9 public notification when closing a pharmacy: distribution, by at least one of the following  
9.10 means, of a notice that informs patients that the pharmacy will close on a specified  
9.11 date and that gives the name, address, and telephone number of the pharmacy to which  
9.12 prescription files will be transferred:

9.13 A. publication of the notice in a local newspaper for one week prior to the  
9.14 date on which the pharmacy is to be closed;

9.15 B. a direct mailing to patients who have had at least one prescription filled at  
9.16 that pharmacy during the six months preceding the date of closing, with the mailing  
9.17 designed to reach patients no later than one business day prior to the closing; and

9.18 C. distribution of the notice to patients who are picking up prescriptions at least  
9.19 30 days prior to the date on which the pharmacy will be closed.

9.20 **6800.1050 REQUIRED REFERENCE BOOKS AND EQUIPMENT.**

9.21 Subpart 1. **Reference books.** Except as indicated, the references in this subpart  
9.22 may be in electronic or hard copy form. In addition to the most recent editions of the  
9.23 laws relating to the practice of pharmacy, the rules of the Board of Pharmacy, and the  
9.24 current copy of the Drug Enforcement Agency regulations, Code of Federal Regulations,  
9.25 title 21, parts 1300 to 1316, each pharmacy in Minnesota must have on file at least one

10.1 current reference from each of the categories in items A to C. At least one dosage and  
10.2 toxicology reference must be in hard copy form that is appropriate to the majority of the  
10.3 patient base of the pharmacy. An equivalent reference approved by the board in writing  
10.4 may be used in an appropriate category.

10.5 A. Examples of pharmacotherapy references are:

10.6 ~~(1) Pharmacology in Medicine;~~

10.7 ~~(2) (1) Goodman and Gilman's The Pharmacological Basis of Therapeutics;~~

10.8 ~~(3) (2) Applied Therapeutics: The Clinical Use of Drugs;~~

10.9 ~~(4) (3) Pharmacotherapy: A Pathophysiologic Approach; and~~

10.10 ~~(5) United States Pharmacopeia -- Dispensing Information; and~~

10.11 ~~(6) (4) Conn's Current Therapy.~~

10.12 [For text of item B, see M.R.]

10.13 C. Examples of general references are:

10.14 [For text of subitems (1) and (2), see M.R.]

10.15 ~~(3) Remington's Pharmaceutical Sciences Remington: The Science and~~  
10.16 ~~Practice of Pharmacy;~~

10.17 [For text of subitems (4) and (5), see M.R.]

10.18 ~~(6) Orange Book: Approved Drug Products with Therapeutic Equivalence~~  
10.19 ~~Evaluations; and~~

10.20 ~~(7) The Merck Manual.~~

10.21 In addition to items A to C, long-term care pharmacies must have on file the most  
10.22 recent edition of Minnesota Department of Health rules pertaining to medication handling  
10.23 in long-term care facilities and a current general reference on geriatric pharmacotherapy.

11.1 In addition to items A to C, specialty pharmacies serving a unique population must have a  
11.2 current general reference appropriate to the patient base served.

11.3 Subp. 2. **Equipment.** Each pharmacy must have the following minimum equipment,  
11.4 clean and in good working order:

11.5 [For text of items A to D, see M.R.]

11.6 E. a refrigerator used only for drug storage or a separate compartment used only  
11.7 for drug storage within a general use refrigerator, manual, electromechanical, or electronic  
11.8 temperature recording equipment, devices, or logs shall be used to document proper  
11.9 storage of ~~prescription~~ legend drugs every business day;

11.10 [For text of items F and G, see M.R.]

11.11 [For text of subp 3, see M.R.]

## 11.12 **6800.1250 APPLICATIONS FOR LICENSURE.**

11.13 Subpart 1. **Submitting Graduates of colleges or schools of pharmacy accredited**  
11.14 **by the Accreditation Council for Pharmacy Education (ACPE).** An applicant for  
11.15 licensure by examination who is a graduate of a college or school of pharmacy accredited  
11.16 by ACPE shall submit a completed eligibility application ~~for examination including,~~  
11.17 affidavits of internship, a copy of the applicant's official and certified birth record, and  
11.18 a recent photograph. An applicant shall ~~show evidence of graduation~~ provide the board  
11.19 with an official certified final transcript from an ACPE accredited college or school of  
11.20 pharmacy showing the date on which the applicant graduated with a bachelor of science  
11.21 degree or doctor of pharmacy degree, as the first professional undergraduate degree in  
11.22 pharmacy, ~~from a college of pharmacy or a department of pharmacy of a university~~  
11.23 ~~approved by the board. The college or department of pharmacy must meet at least the~~  
11.24 ~~minimum standards set by the American Council on Pharmaceutical Education in the~~  
11.25 ~~current edition of its accreditation manual or, for Canadian graduates, must meet at least~~

12.1 ~~the minimum standards set by the Canadian Council for Accreditation of Pharmacy~~  
12.2 ~~Programs and must conduct its instruction in English. The evidence shall be shown by~~  
12.3 ~~submitting an official final transcript showing the date on which a degree was conferred.~~  
12.4 ~~The documents in this subpart, together with a check for \$125 the application fee under~~  
12.5 ~~Minnesota Statutes, chapter 151, and made payable to the Minnesota Board of Pharmacy,~~  
12.6 ~~must be received by the board prior to approval being granted to sit for the examinations.~~  
12.7 ~~Applicants participating in the North American Pharmacy Licensing Exam (NAPLEX)~~  
12.8 ~~and the Multistate Pharmacy Jurisprudence Exam (MPJE) must complete a separate~~  
12.9 ~~application for these exams and submit the applications to the board. A certified check~~  
12.10 ~~or money order for these exams made payable to the National Association of Boards of~~  
12.11 ~~Pharmacy (NABP) must be submitted to NABP after the applications for examination~~  
12.12 ~~have been approved by the board. An applicant who is a graduate of a school or college of~~  
12.13 ~~pharmacy located outside the United States or Canada, which has not been recognized and~~  
12.14 ~~approved by the board, but who is otherwise qualified to apply for a license to practice~~  
12.15 ~~pharmacy in this state, is considered to have satisfied the requirements of graduation if~~  
12.16 ~~the applicant verifies to the board the applicant's academic record and the applicant's~~  
12.17 ~~graduation. Before taking the licensing examination, a foreign graduate applicant shall~~  
12.18 ~~pass the Foreign Pharmacy Graduate Equivalency Examination, which is recognized~~  
12.19 ~~and approved by the board, given by the Foreign Pharmacy Graduate Examination~~  
12.20 ~~Commission and demonstrate proficiency in the English language by passing the Test of~~  
12.21 ~~English as a Foreign Language, which is recognized and approved by the board, given by~~  
12.22 ~~the Educational Testing Service as a prerequisite to taking the licensure examination. The~~  
12.23 ~~board shall consider an application for licensure by examination or a NAPLEX or MPJE~~  
12.24 ~~registration to be invalid 18 months after the date that the board determines an application~~  
12.25 ~~or registration form is complete. An applicant whose application or registration form is~~  
12.26 ~~invalid, and who wishes to continue licensure procedures, shall submit a new application~~  
12.27 ~~or registration form and fee. Applicants must register with and pay the required fees to the~~

13.1 National Association of Boards of Pharmacy for the North American Pharmacy Licensing  
13.2 Exam and the Multistate Pharmacy Jurisprudence Exam, both of which must be passed  
13.3 before licensure as a pharmacist is granted.

13.4 Subp. 1a. **Graduates of colleges or schools of pharmacy accredited by the**  
13.5 **Canadian Council for Accreditation of Pharmacy Programs (CCAPP).**

13.6 A. Applicants who graduated between 1993 and June 30, 2004, from a  
13.7 CCAPP-accredited pharmacy program with a curriculum taught in English must:

13.8 (1) submit a letter to the Board of Pharmacy which outlines work  
13.9 experience as an intern or pharmacist in Canada. The board shall determine if the  
13.10 reported experience is comparable to the experience gained by individuals completing the  
13.11 internship requirement specified in part 6800.5400. If the board finds that the reported  
13.12 experience is not comparable, the board shall require the applicant to obtain additional  
13.13 experience as an intern or pharmacist prior to permitting the applicant to sit for the  
13.14 required licensure examinations;

13.15 (2) submit to the board a completed eligibility application, a copy of the  
13.16 applicant's official certified birth record, a recent photograph, an official certified final  
13.17 transcript from a CCAPP-accredited college or school of pharmacy showing the date on  
13.18 which the applicant graduated with a first professional pharmacy degree, and a check for  
13.19 the application fee under Minnesota Statutes, chapter 151; and

13.20 (3) register with and pay the required fees to the National Association  
13.21 of Boards of Pharmacy for the North American Pharmacy Licensing Exam and the  
13.22 Multistate Pharmacy Jurisprudence Exam, both of which must be passed before licensure  
13.23 as a pharmacist is granted.

13.24 B. Applicants who graduated before 1993 or after June 30, 2004, from a  
13.25 CCAPP-accredited pharmacy program with a curriculum taught in English or who  
13.26 graduated from a CCAPP-accredited pharmacy program with a curriculum that is not

14.1 taught in English or licensed Canadian pharmacists who graduated from a college of  
14.2 pharmacy located outside of the United States or Canada must:

14.3 (1) pass the Foreign Pharmacy Graduate Equivalency Examination and  
14.4 become certified by the Foreign Pharmacy Graduate Equivalency Commission (FPGEC),  
14.5 including demonstrating proficiency in the English language by passing the Test of  
14.6 English as a Foreign Language (TOEFL) and the Test of Spoken English, or the TOEFL  
14.7 Internet-based Test;

14.8 (2) obtain 1,600 hours of internship after becoming certified by the FPGEC.  
14.9 Applicants obtaining their internship in Minnesota must register as interns according to  
14.10 part 6800.5300 and complete the internship manual as specified in that part. Applicants  
14.11 obtaining their internship outside of Minnesota must have the licensing agency of the state  
14.12 in which the internship was completed certify to the board completion of the internship  
14.13 hours;

14.14 (3) submit to the board a completed eligibility application form, a copy  
14.15 of the applicant's official certified birth record, a recent photograph, and a check for the  
14.16 application fee under Minnesota Statutes, chapter 151; and

14.17 (4) register with and pay the required fees to the National Association  
14.18 of Boards of Pharmacy for the North American Pharmacy Licensing Exam and the  
14.19 Multistate Pharmacy Jurisprudence Exam, both of which must be passed before licensure  
14.20 as a pharmacist is granted.

14.21 Subp. 1b. **Foreign pharmacy graduates.**

14.22 A. Except as provided in subpart 2, graduates of foreign schools, colleges,  
14.23 or programs of pharmacy must:

14.24 (1) pass the Foreign Pharmacy Graduate Equivalency Examination and  
14.25 become certified by the Foreign Pharmacy Graduate Equivalency Commission (FPGEC),

15.1 including demonstrating proficiency in the English language by passing the Test of  
15.2 English as a Foreign Language (TOEFL) and the Test of Spoken English, or the TOEFL  
15.3 Internet-based Test;

15.4 (2) obtain 1,600 hours of internship after becoming certified by the FPGEC.  
15.5 Applicants obtaining their internship in Minnesota must register as interns according to  
15.6 part 6800.5300 and complete the internship manual as specified in that part. Applicants  
15.7 obtaining their internship outside of Minnesota must have the licensing agency of the state  
15.8 in which the internship was completed certify to the board completion of the internship  
15.9 hours;

15.10 (3) submit to the board a completed eligibility application form, a copy  
15.11 of the applicant's official certified birth record, a recent photograph, and a check for the  
15.12 application fee under Minnesota Statutes, chapter 151; and

15.13 (4) register with and pay the required fees to the National Association  
15.14 of Boards of Pharmacy for the North American Pharmacy Licensing Exam and the  
15.15 Multistate Pharmacy Jurisprudence Exam, both of which must be passed before licensure  
15.16 as a pharmacist is granted.

15.17 B. Graduates of four-year foreign pharmacy schools, colleges, or programs are  
15.18 not eligible for licensure as pharmacists.

15.19 Subp. 1c. **Social Security number required.** No license will be issued to an  
15.20 applicant for licensure by any method described in this part who does not supply the board  
15.21 with a valid United States Social Security number as required by Minnesota Statutes,  
15.22 section 270C.72, subdivision 4.

15.23 Subp. 1a ~~1d~~. **Authorization to practice.** An applicant who obtains a passing  
15.24 score on the ~~examination~~ required examinations is authorized to practice pharmacy only  
15.25 after paying an original licensure fee of \$105 under Minnesota Statutes, chapter 151, to  
15.26 the board.

16.1 Subp. 2. **Retaking exam.** Any applicant who has failed to pass ~~the~~ an examination  
16.2 required by Minnesota Statutes, section 151.06, 151.07, 151.10, or 151.12, may retake  
16.3 the examination within the next ensuing ~~14~~ 18 months, provided that no applicant who  
16.4 has failed in three examinations shall be permitted to take a further examination, except  
16.5 upon petition setting forth facts acceptable to the board. ~~The applicant shall, at least 45~~  
16.6 ~~days before an examination, notify the board in writing of the intention to retake the~~  
16.7 ~~examination, certifying that information furnished on the original application remains~~  
16.8 ~~true and correct, or reporting any changes therein, including additional education and~~  
16.9 ~~experience, and shall submit a fee, as described in subpart 1. The board reserves the right~~  
16.10 ~~to request~~ resubmission of a full and complete application, including the application  
16.11 fee under Minnesota Statutes, chapter 151.

16.12 Subp. 2a. **Deadline for completion of licensing process.** The board shall consider  
16.13 an application for licensure or a NAPLEX or MPJE registration to be invalid 18 months  
16.14 after the date that the board receives an application for licensure.

16.15 Subp. 3. **Fees not refunded.** ~~Examination or license~~ Fees paid to the board shall  
16.16 according to this part will not be returned or refunded.

16.17 **6800.1300 LICENSURE TRANSFER (RECIPROCITY).**

16.18 Subpart 1. **Applications.** An application for ~~reciprocal~~ licensure transfer (licensure  
16.19 as a pharmacist on the basis of licensure as a pharmacist in another state) together with a  
16.20 an application fee of \$205 under Minnesota Statutes, chapter 151, shall be filed with the  
16.21 director of the board ~~at least 30 days before the date the application is to be considered~~  
16.22 ~~by the board.~~ An applicant must register with and pay the required fees to the National  
16.23 Association of Boards of Pharmacy for the Minnesota version of the Multistate Pharmacy  
16.24 Jurisprudence Exam, which must be passed before licensure as a pharmacist is granted.

16.25 Subp. 2. **Eligibility.** To be found eligible for consideration by the board:



17.1 ~~A. an applicant must have practiced in the profession for at least one year after~~  
17.2 ~~licensure in another state which is an active member of the National Association of Boards~~  
17.3 ~~of Pharmacy before the applicant will be considered eligible to reciprocate to Minnesota;~~

17.4 B A. an applicant, if examined and licensed before January 1, 1973, shall show  
17.5 that the applicant has acquired 2,080 hours of practical pharmacy experience under the  
17.6 instruction of a licensed pharmacist;

17.7 € B. an applicant, if examined and licensed after between January 1, 1973,  
17.8 and May 1, 2003, shall show that the applicant has acquired 1,500 hours of practical  
17.9 pharmacy experience under the instruction of a licensed pharmacist, to be acquired  
17.10 after the successful completion of the ~~third~~ first professional academic year of the  
17.11 standard five-year or six-year pharmacy curriculum, 400 hours of which may be acquired:  
17.12 concurrently with college attendance, in clinical pharmacy programs, or in demonstration  
17.13 projects which have been approved by the Tripartite Committee on Internship and the  
17.14 board of the active member state from which the applicant applies; and

17.15 C. an applicant, if examined and licensed after May 1, 2003, shall show that the  
17.16 applicant has acquired 1,600 hours of practical pharmacy experience under the instruction  
17.17 of a licensed pharmacist, acquired after the successful completion of the first professional  
17.18 academic year of the standard six-year pharmacy curriculum, with 800 of the hours being  
17.19 of a traditional compounding, patient counseling, and dispensing nature.

17.20 [For text of subps 3 and 4, see M.R.]

17.21 Subp. 5. **Examination.** Applicants for ~~reciprocal~~ licensure transfer shall be required  
17.22 to display their familiarity with the laws regulating the practice of pharmacy in Minnesota  
17.23 by ~~submitting to an examination on the Minnesota laws and rules and the federal laws~~  
17.24 ~~and regulations governing the practice of pharmacy~~ passing the Minnesota version of the  
17.25 Multistate Pharmacy Jurisprudence Exam that is offered by the National Association  
17.26 of Boards of Pharmacy.

18.1 Subp. 6. [See repealer.]

18.2 **6800.1400 DRUG MANUFACTURER OR WHOLESALER LICENSE.**

18.3 Subpart 1. **Licensing; fees.** Every person engaged in manufacturing, wholesale  
18.4 distribution, or selling of drugs, medicines, chemicals, or poisons for medicinal purposes  
18.5 other than to the consuming public or patient, except as allowed under part 6800.9921,  
18.6 shall annually be licensed by the board. Upon the filing of an application, and upon  
18.7 payment of a fee of ~~\$180 for manufacturing or wholesale distribution of prescription~~  
18.8 ~~drugs only, not including medical gases; \$180 for manufacturing or wholesale distribution~~  
18.9 ~~of prescription and nonprescription drugs, not including medical gases; \$155 for~~  
18.10 ~~manufacturing or wholesale distribution of nonprescription drugs or veterinary drugs only;~~  
18.11 ~~\$130 for manufacturing or wholesale distribution of prescription medical gases only; and~~  
18.12 ~~\$105 for licensed pharmacies engaged in wholesale distribution~~ under Minnesota Statutes,  
18.13 chapter 151, the board may issue or renew a license in such form as it may prescribe to  
18.14 the manufacturer or wholesale distributor. The license shall be exposed in a conspicuous  
18.15 place in the manufacturer's or wholesaler's place of business for which it is issued, shall  
18.16 expire at midnight on June 1 of each year, and shall be renewed annually upon the filing of  
18.17 an application therefor, on or before May 1 of each year together with the applicable fee.  
18.18 Renewal applications received after June 1 shall be subject to a late filing fee of one-half  
18.19 of the renewal fee in addition to the amount of the renewal fee. An application for a  
18.20 manufacturer or wholesaler license which has not been completed within 12 months of the  
18.21 date on which the board received the application is no longer valid.

18.22 [For text of subp 2, see M.R.]

18.23 Subp. 3. **Separate licenses required.** A separate license is required for each  
18.24 separate location ~~where drugs are stored~~ involved in wholesale drug distribution within  
18.25 this state. ~~Out-of-state wholesale drug distributors shipping drugs into Minnesota who do~~  
18.26 ~~not maintain or operate a physical facility within Minnesota are not required to license~~

19.1 ~~each separate location from which drugs are shipped to Minnesota, but may instead obtain~~  
19.2 ~~licensure for the primary location of the parent entity and any divisions, subsidiaries, or~~  
19.3 ~~affiliated companies.~~ and each separate out-of-state location from which drugs are shipped  
19.4 into this state. A manufacturer that does not ship drugs into this state from any location  
19.5 that it directly operates must still obtain a license according to Minnesota Statutes, section  
19.6 151.25, if it does business with accounts in this state. Doing business in this state includes  
19.7 any sale of a manufacturer's drug to any individual or business in Minnesota.

19.8 **6800.1430 PERSONNEL.**

19.9 Each wholesale drug distributor shall require each person employed in any  
19.10 ~~prescription~~ drug wholesale activity to have enough education, training, and experience,  
19.11 in any combination, sufficient for that person: (1) to do assigned work in a manner  
19.12 that maintains the quality, safety, and security of the drug products in accordance with  
19.13 parts 6800.1400 to 6800.1440; and (2) to assume responsibility for compliance with the  
19.14 licensing requirements of parts 6800.1400 to 6800.1440.

19.15 **6800.1440 REQUIREMENTS FOR WHOLESALE DRUG DISTRIBUTORS.**

19.16 [For text of subp 1, see M.R.]

19.17 Subp. 2. **Incorporation by reference.** "United States Pharmacopeia/National  
19.18 Formulary" means the United States Pharmacopeia/National Formulary published by  
19.19 the United States Pharmacopeial Convention Inc. (~~Rockville, Maryland, 1990~~), which  
19.20 is incorporated by reference. A wholesale drug distributor must follow the standards set  
19.21 forth in the most recent edition of the United States Pharmacopeia/National Formulary.  
19.22 The United States Pharmacopeia/National Formulary is subject to frequent change. The  
19.23 book is available for inspection and copying at the Biomedical Library, University of  
19.24 Minnesota, Diehl Hall, 505 Essex Street S.E., Minneapolis, Minnesota 55455, or through  
19.25 the Minitex interlibrary loan system.

20.1 Subp. 3. **Facilities.** All facilities at which ~~prescription~~ drugs are stored, warehoused,  
20.2 handled, held, offered, marketed, or displayed shall:

20.3 [For text of items A and B, see M.R.]

20.4 C. have a physically separate area for storage of all ~~prescription~~ drugs that are  
20.5 outdated, damaged, deteriorated, misbranded, or adulterated, or that are in immediate or  
20.6 sealed, secondary containers that have been opened;

20.7 [For text of items D and E, see M.R.]

20.8 Subp. 4. **Security.** The requirements in items A to C govern security.

20.9 A. All facilities used for wholesale drug distribution shall be secure from  
20.10 unauthorized entry as follows:

20.11 [For text of subitems (1) and (2), see M.R.]

20.12 (3) entry into areas where ~~prescription~~ drugs are held shall be limited  
20.13 to authorized personnel.

20.14 [For text of items B and C, see M.R.]

20.15 [For text of subp 5, see M.R.]

20.16 Subp. 6. **Examination of materials.** Upon receipt, each outside shipping container  
20.17 shall be visually examined for identity and to prevent the acceptance of contaminated  
20.18 drugs or drugs that are otherwise unfit for distribution. This examination shall be adequate  
20.19 to reveal container damage that would suggest possible contamination or other damage  
20.20 to the contents.

20.21 Each outgoing shipment shall be carefully inspected for identity of the ~~prescription~~  
20.22 drug products and to ensure that there is no delivery of drugs that have been damaged in  
20.23 storage or held under improper conditions.

20.24 The record keeping requirements in subpart 8 shall be followed for all incoming  
20.25 and outgoing drugs.

21.1 Subp. 7. **Returned, damaged, and outdated drugs.** Items A to D govern returned,  
21.2 damaged, outdated, deteriorated, misbranded, and adulterated drugs.

21.3 [For text of item A, see M.R.]

21.4 B. Any ~~prescription~~ drugs whose immediate or sealed outer or sealed secondary  
21.5 containers have been opened or used shall be identified as such, and shall be physically  
21.6 separated from other drugs until they are either destroyed or returned to the supplier.

21.7 [For text of items C and D, see M.R.]

21.8 [For text of subp 8, see M.R.]

21.9 Subp. 9. **Written policies and procedures.** Wholesale drug distributors shall  
21.10 establish, maintain, and adhere to written policies and procedures, which shall be followed  
21.11 for the receipt, security, storage, inventory, and distribution of drugs. They must include  
21.12 policies and procedures for identifying, recording, and reporting losses or thefts and for  
21.13 correcting all errors and inaccuracies in inventories. Wholesale drug distributors shall  
21.14 include the written policies and procedures described in items A to D.

21.15 [For text of items A to C, see M.R.]

21.16 D. A procedure to ensure that any outdated ~~prescription~~ drugs shall be  
21.17 segregated from other drugs and either returned to the manufacturer or destroyed. This  
21.18 procedure shall provide for written documentation of the disposition of outdated drugs.  
21.19 This documentation shall be maintained for two years after disposition of the outdated  
21.20 drugs.

21.21 [For text of subps 10 to 12, see M.R.]

## 21.22 **6800.1500 CONTINUING PHARMACY EDUCATION.**

21.23 Subpart 1. **Definitions.** ~~Definitions:~~

22.1 A. "Approved continuing education" means those continuing pharmacy or  
22.2 pharmacy technician education programs approved by the board or made available by  
22.3 an approved provider. These programs may take the form of classes, conferences,  
22.4 correspondence study courses, institutes, lectures, professional meetings, programmed  
22.5 learning courses, journal readings, seminars, study groups, or other program formats  
22.6 commonly accepted by educators as legitimate adult educational activities.

22.7 [For text of item B, see M.R.]

22.8 C. "Continuing pharmacy education" is a planned learning experience beyond a  
22.9 formal undergraduate degree program designed to promote the continual development of  
22.10 professional knowledge, professional skills, and professional attitudes on the part of the  
22.11 ~~practitioners~~ pharmacist and shall include but is not limited to professional postgraduate  
22.12 education in any of the following subjects:

22.13 [For text of subitems (1) to (4), see M.R.]

22.14 D. "Continuing pharmacy technician education" is a planned learning  
22.15 experience beyond initial technician training designed to promote the continued  
22.16 development of the knowledge, skills, and attitudes that enable a technician to adequately  
22.17 perform the tasks that a technician is allowed to perform under this part.

22.18 Subp. 2. **Minimum hours required for pharmacists; reporting.** Beginning March  
22.19 4, 1975, no annual license renewal shall be issued to a pharmacist under Minnesota  
22.20 Statutes, section 151.13, until the pharmacist has submitted to the board satisfactory  
22.21 evidence that the pharmacist has completed at least 30 hours of approved continuing  
22.22 education during the previous two-year period. Thereafter, a pharmacist shall submit the  
22.23 evidence every two years. Pharmacists exempted from the payment of all renewal fees  
22.24 and from the filing of any application for renewal under Minnesota Statutes, section  
22.25 326.56, subdivision 2, shall also be exempted from the requirements of this subpart  
22.26 for a concurrent period of time. Beginning with the 1981-1983 reporting period,

23.1 participation in continuing education shall be reported ~~on October 1~~ by September 30  
23.2 of each even-numbered year. The board may grant a pharmacist, on application, an  
23.3 extension of time not to exceed one year to comply with the requirements of this subpart.  
23.4 The extension shall not relieve the pharmacist from complying with the continuing  
23.5 education requirements for any other two-year period. Each pharmacist is responsible for  
23.6 maintaining a complete record of the pharmacist's continuing education participation  
23.7 during each continuing education reporting cycle.

23.8 Subp. 2a. **Minimum hours required for technicians; reporting.**

23.9 A. A pharmacy technician's registration renewal for calendar year 2014 shall  
23.10 not be issued unless the technician has completed 20 hours of approved continuing  
23.11 pharmacy technician education during the two-year period between August 1, 2011, and  
23.12 July 31, 2013. Thereafter, no annual pharmacy technician registration renewal shall be  
23.13 issued unless the technician presents the board with satisfactory evidence of completion of  
23.14 20 hours of approved continuing pharmacy technician education per two-year reporting  
23.15 period. Each reporting period shall end on July 31 of odd-numbered years.

23.16 B. Continuing education must focus on the competencies that the technician  
23.17 must carry out and the specific duties that the technician performs. Technicians exempted  
23.18 from the payment of all renewal fees and from the filing of any application for renewal  
23.19 under Minnesota Statutes, section 326.56, subdivision 2, shall also be exempted from  
23.20 the requirements of this subpart for a concurrent period of time. The board may grant a  
23.21 technician, on application, an extension of time not to exceed one year to comply with  
23.22 the requirements of this subpart. The extension shall not relieve the technician from  
23.23 complying with the continuing education requirements for any other two-year period.  
23.24 Each technician is responsible for maintaining a complete record of continuing education  
23.25 participation during each continuing education reporting cycle.

23.26 [For text of subps 3 to 4, see M.R.]

24.1 Subp. 4a. **Programs not previously submitted for approval.** A pharmacist or  
24.2 pharmacy technician may apply for credit for attendance at programs not previously  
24.3 submitted to the board for approval provided that the pharmacist or pharmacy technician  
24.4 completes a continuing education program approval form, obtainable from the board, and  
24.5 submits it to the board within ~~45~~ 90 days after completing the program. The applicant  
24.6 shall provide, at a minimum, the title, site, date, type, and length of the program being  
24.7 proposed for approval, a program outline, and a description of the type of evaluation  
24.8 mechanism used at the program. Approval of the program is subject to all the standards of  
24.9 Minnesota Statutes, section 214.12, and subparts 1, item C, and 3a, items B to G.

24.10 [For text of subp 5, see M.R.]

24.11 Subp. 6. **Credit for presentation of professional lectures.** Pharmacists may apply  
24.12 for credit for presentation of in-service training programs or lectures consisting of subjects  
24.13 included in the definition of Continuing ~~Pharmaceutical~~ Pharmacy Education. Credit for  
24.14 these presentations will be granted only once to any individual during any reporting period.

24.15 Subp. 6a. **Credit for preceptor training program.** A pharmacist who applies  
24.16 shall be given continuing education credit for participation in ~~the Board of Pharmacy's~~  
24.17 any instructional program for pharmacist preceptors that is developed or approved by  
24.18 the board.

24.19 [For text of subps 7 to 9, see M.R.]

24.20 **6800.2250 UNPROFESSIONAL CONDUCT.**

24.21 Subpart 1. **Prohibited conduct.** Unprofessional conduct shall include, but is not  
24.22 limited to, the following acts of a pharmacist or pharmacy:

24.23 [For text of items A and B, see M.R.]



25.1 C. Refusing to compound and dispense ~~prescriptions~~ prescription drug orders  
 25.2 that may reasonably be expected to be compounded or dispensed in pharmacies by  
 25.3 pharmacists, except as provided for in Minnesota Statutes, sections 145.414 and 145.42.

25.4 [For text of item D, see M.R.]

25.5 E. Discriminating in any manner between patients or groups of patients, for  
 25.6 reasons of ~~religion~~, race, ~~ereed~~, color, ~~sex~~, ~~age~~, creed, religion, disability, national origin,  
 25.7 marital status, sexual orientation, sex, or disease age.

25.8 F. Refusing to consult with patrons or patients, attempting to circumvent  
 25.9 the consulting requirements, or discouraging the patient from receiving consultation  
 25.10 concerning contents, therapeutic values, uses, and prices of ~~prescription~~ legend or  
 25.11 ~~nonprescription~~ nonlegend drugs, chemicals, or poisons.

25.12 [For text of items G to J, see M.R.]

25.13 K. Engaging in any pharmacy practice which constitutes a danger to the health,  
 25.14 welfare, or safety of a patient or the public, including but not limited to, practicing in a  
 25.15 manner which substantially departs from the standard of care ordinarily exercised by a  
 25.16 pharmacist and which harms or could harm a patient.

25.17 Subp. 2. **Improper advertising.** ~~Prescription~~ Legend drug price information may  
 25.18 be provided to the public only by a pharmacy, so long as it is not violative of any federal  
 25.19 or state laws applicable to the advertisement of such articles generally and if all of the  
 25.20 following conditions are met:

25.21 [For text of items A to C, see M.R.]

25.22 [For text of subps 3 and 4, see M.R.]

25.23 **6800.2400 PHARMACIST-IN-CHARGE.**

25.24 [For text of subps 1 to 3, see M.R.]

26.1 Subp. 4. **Termination of service.** Each pharmacy shall notify the Board of Pharmacy  
26.2 immediately upon knowledge of the termination of the services of the pharmacist-in-charge  
26.3 and further, shall immediately designate a successor pharmacist-in-charge and immediately  
26.4 notify the Board of Pharmacy of such designation. The Board of Pharmacy upon receiving  
26.5 such notice shall furnish the successor pharmacist-in-charge such form or forms as it may  
26.6 from time to time prescribe which form or forms must be completed by the successor  
26.7 pharmacist-in-charge and filed with the Board of Pharmacy within ten days after receipt  
26.8 thereof. The successor pharmacist-in-charge shall submit, on the approved form, an  
26.9 acknowledgment of an awareness and understanding of any variances that the pharmacy  
26.10 has been granted according to part 6800.9900. The successor pharmacist-in-charge shall  
26.11 be responsible for ensuring that any conditions imposed by the board on granted variances  
26.12 continue to be met.

26.13 **6800.2600 VENDING MACHINES AUTOMATED COUNTING AND**  
26.14 **DISTRIBUTION.**

26.15 Subpart 1. **Generally.** It is unlawful to count, distribute, dispense, or vend any  
26.16 legend drug by automatic through the use of an automated counting device or automated  
26.17 drug distribution system, or a vending machine without first providing the board with  
26.18 except as provided in this part.

26.19 **A. Notification.** The board must be provided with written notification of the  
26.20 location of the automated medication management counting device or automated drug  
26.21 distribution system, the name and address of the pharmacy responsible for control of the  
26.22 device or system, written policies and procedures that govern the operation and patient  
26.23 safety of the device or system, and the name of the pharmacist-in-charge of the pharmacy.  
26.24 ~~Nothing in this part prohibits a licensed hospital receiving pharmaceutical services from a~~  
26.25 ~~licensed pharmacy on the premises from utilizing such a device in an emergency, after~~  
26.26 ~~regular pharmacy hours, when the hospital's pharmacist has complete control over the~~  
26.27 ~~monitoring of drug therapy, packaging, labeling, filling, record keeping, and security of~~

27.1 ~~the drugs involved and of the device, and when the device is utilized in compliance with~~  
27.2 ~~all other state and federal laws and regulations regarding the distribution of legend drugs.~~  
27.3 ~~In addition, nothing in this part prevents a licensed hospital, receiving pharmaceutical~~  
27.4 ~~service from a licensed pharmacy on the premises, from using an automated medication~~  
27.5 ~~management system as its primary drug distribution system if the system requires that~~  
27.6 ~~drug orders are reviewed and released by a pharmacist before hospital nursing staff are~~  
27.7 ~~allowed access to the drug. Notification must be provided to the board at least 60 days in~~  
27.8 ~~advance of the initial use of the device or system. Policies and procedures must address~~  
27.9 ~~staff training and the requirements listed in subparts 2 and 3.~~

27.10 ~~Use of automated medication management systems at sites remote from the location~~  
27.11 ~~of the pharmacy responsible for the system must be approved by the board before~~  
27.12 ~~installation and implementation. Requests for approval must be submitted in writing and~~  
27.13 ~~must include a copy of the policies and procedures which will govern the operation of the~~  
27.14 ~~system. The board shall grant approval if it determines that:~~

27.15 ~~A. the approval will not adversely affect, directly or indirectly, the health,~~  
27.16 ~~safety, or well-being of the public;~~

27.17 ~~B. the measures to be taken in the use of the automated system are equivalent or~~  
27.18 ~~superior to those of a more traditional unit dose or other dispensing system; and~~

27.19 ~~C. the system requires that drug orders are reviewed and released by a~~  
27.20 ~~pharmacist before facility staff are allowed access to the drug.~~

27.21 ~~The board shall deny approval if it determines that item A, B, or C has not been met.~~

27.22 ~~B. **Training.** Training for all staff who use an automated counting device or~~  
27.23 ~~automated drug distribution system shall be conducted by qualified individuals on a~~  
27.24 ~~continuing basis and with sufficient frequency to ensure that employees remain familiar~~  
27.25 ~~with the relevant policies and procedures and with the safe operation of the device.~~  
27.26 ~~Documentation of training must be maintained and must include the names and unique~~

28.1 identifiers of staff members trained, the name and unique identifier of the trainer, and the  
28.2 date of training. Training documentation shall be made available to the board or the  
28.3 board's staff upon request.

28.4 Subp. 2. **Automated counting devices.** In addition to the requirements in subpart 1,  
28.5 the following requirements apply to automated counting devices.

28.6 A. The filling of cells or cassettes is considered to be prepackaging subject to  
28.7 the requirements of part 6800.3200, subpart 1. Only one cell or cassette may be filled at  
28.8 a time. Drugs previously removed from a manufacturer's stock container may not be  
28.9 used to fill a cell or cassette. No drug may be distributed from an automated counting  
28.10 device unless a pharmacist certifies the accuracy of the filling of each cell or cassette. All  
28.11 manufacturer stock containers used to fill a cell or cassette must be available for the  
28.12 pharmacist to check during the certification process.

28.13 B. The labeling of cells and cassettes is subject to the requirements of part  
28.14 6800.3200, subpart 2.

28.15 C. The pharmacy shall have a method to calibrate and verify the accuracy of  
28.16 the automated counting device and document the calibration and verification on a regular  
28.17 basis, consistent with the recommendations of the manufacturer of the device.

28.18 D. The pharmacy shall have procedures in place to prevent cross-contamination  
28.19 of cells and cassettes.

28.20 E. If the manufacturer's stock container is not available as required in part  
28.21 6800.3100, subpart 3, a method for verifying that the correct drug is being dispensed must  
28.22 be specified in the policies and procedures. All other certification requirements in part  
28.23 6800.3100, subpart 3, shall apply.

28.24 F. The pharmacy must have continuous quality assurance policies and  
28.25 procedures developed specifically for the automated counting device.

29.1 Subp. 3. Automated drug distribution systems. In addition to the requirements in  
29.2 subpart 1, the following requirements apply to automated drug distribution systems.

29.3 A. A pharmacist employed by the pharmacy, which is responsible for the  
29.4 control of the system, must review, interpret, and approve all prescription drug orders  
29.5 before any drug is distributed from the system to be administered to a patient. Access to  
29.6 drugs when a pharmacist has not reviewed and approved the prescription drug order is  
29.7 permitted only when a formal and written decision to allow such access is issued by the  
29.8 pharmacy and therapeutics committee or its equivalent. The committee must specify the  
29.9 patient care circumstances in which such access is allowed, the drugs that can be accessed,  
29.10 and the staff that are allowed to access the drugs.

29.11 B. Access to any automated medication distribution system must be limited to  
29.12 pharmacy and nonpharmacy personnel authorized to procure drugs from the system. Each  
29.13 person authorized to access the system must be assigned an individual, specific access  
29.14 code. Alternatively, access to the system may be controlled through the use of biometric  
29.15 identification procedures. A policy specifying time access parameters, such as time-outs,  
29.16 log-offs, and lock-outs must be in place.

29.17 C. At a minimum, the system must maintain records of:

29.18 (1) the identity of all personnel who access the automated unit, including  
29.19 any personnel who are required to witness a transaction;

29.20 (2) the reason for access;

29.21 (3) the date and time of access;

29.22 (4) the name, strength, dosage form, and quantity of the drug removed,  
29.23 returned, or wasted;

29.24 (5) the name of the patient for whom the drug was ordered; and

30.1           (6) any additional information the pharmacist in charge may deem  
30.2 necessary.

30.3 These records shall be reviewed for discrepancies on a periodic basis. The  
30.4 pharmacist-in-charge is responsible for the quality, accuracy, and timeliness of the review  
30.5 and must ensure that appropriate actions are taken to deal with any discrepancies found.

30.6           D. The pharmacy and therapeutics or equivalent committee shall develop and  
30.7 regularly review a list of drugs prohibited from being distributed through an automated  
30.8 distribution system. The review must take place at least annually. A high-alert drug  
30.9 may be distributed through an automated distribution system only if the pharmacy and  
30.10 therapeutics or equivalent committee has determined that the drug need not be included  
30.11 on the list of drugs prohibited from being distributed through an automated distribution  
30.12 system. Patient-specific drug additions or deletions to the automated distribution device or  
30.13 system shall be determined by a pharmacist.

30.14           E. The use of an open matrix drawer that allows access to more than one drug at  
30.15 a time must be limited to noncontrolled substance drugs, unless the entire drawer contains  
30.16 only one controlled substance drug product. Noncontrolled substance drugs may be stored  
30.17 in the open matrix drawer if they are:

30.18           (1) large bulky items such as intravenous infusion bags;

30.19           (2) nonlegend drugs that are safely segregated;

30.20           (3) legend drugs that are not look-alike products; or

30.21           (4) drugs properly packaged and labeled for an individual patient.

30.22           F. Whenever possible, removal of high alert drugs from the system should  
30.23 be double-checked by a second licensed health care professional to ensure that the  
30.24 prescription drug order is being correctly interpreted and followed.

31.1 G. A pharmacist must certify all packaging, labeling, and stocking associated  
31.2 with the use of an automated drug distribution system. Unless the certification process  
31.3 utilizes a fail-safe bar coding, certification must be performed by a pharmacist.  
31.4 Certification must be documented and records must be retained for at least two years.

31.5 H. Automated distribution devices must be secured or kept in a locked  
31.6 medication room when not in actual use.

31.7 I. Unused drugs must be returned to the pharmacy or to the system's secure,  
31.8 designated return bin or equivalent area. Restocking of the system may only be performed  
31.9 by designated pharmacy personnel with required certification.

31.10 J. A monthly inspection of automated distribution devices must be performed to  
31.11 ensure, at a minimum, that:

31.12 (1) drugs are properly stored in their assigned locations and in  
31.13 pharmacy-approved configurations;

31.14 (2) outdated drugs are removed and replaced;

31.15 (3) only approved drugs are in the device;

31.16 (4) inventory levels are appropriate based on usage; and

31.17 (5) the device and drugs are secure.

31.18 K. Pharmacy personnel must conduct, at least monthly, an audit of controlled  
31.19 substances to ensure accuracy of distribution and proper record keeping.

31.20 L. The system must provide for maintenance of patient confidentiality, so that  
31.21 unauthorized individuals do not have access to patient data.

31.22 M. Policies and procedures must be in place for return of unused drugs and for  
31.23 drug wastage and the documentation of drug wastage.

32.1 N. Continuous quality assurance must be developed specifically for the  
32.2 automated drug distribution system or device. An ongoing failure mode effect analysis  
32.3 or quality assurance process should be developed that addresses possible system  
32.4 failures, process failures, high-risk drugs, medication errors, and controlled substance  
32.5 discrepancies.

32.6 **6800.3000 PRESCRIPTIONS AND DISTRIBUTION OF MEDICATION DRUGS.**

32.7 Subpart 1. **Acceptance of ~~order~~ prescription drug orders and distribution of**  
32.8 **drugs.**

32.9 A. No licensed pharmacist shall participate in any arrangement or agreement  
32.10 whereby ~~prescriptions~~ prescription drug orders or filled prescriptions may be left at, picked  
32.11 up from, accepted by, or delivered to any place of business not licensed as a pharmacy.  
32.12 This ~~applies to the prescription order blank and to the completed prescription medication~~  
32.13 ~~container.~~ Provided, however, that nothing in this part prohibits a licensed pharmacist or  
32.14 a licensed pharmacy, by means of its employee or by use of a common carrier, from  
32.15 picking up ~~prescriptions~~ prescription drug orders or delivering filled prescriptions at  
32.16 the office or home of the prescriber, at the residence of the patient, or at the hospital or  
32.17 medical long-term care facility in which a patient is confined. A pharmacy may deliver  
32.18 filled prescriptions at the place of employment of the patient or a designated caregiver of  
32.19 the patient only if the pharmacy:

32.20 (1) obtains and maintains the written authorization of the patient or  
32.21 patient's caregiver for delivery at the place of employment;

32.22 (2) ensures the filled prescription order is delivered directly to the patient,  
32.23 the caregiver, or an authorized agent identified in the written authorization; and

32.24 (3) ensures the security of protected health information.



33.1 B. Direct prescription delivery. A pharmacy that employs the United States  
33.2 Postal Service or other common carrier to deliver a filled prescription directly to a patient  
33.3 must, based on the professional judgment of the pharmacist:

33.4 (1) use adequate storage or shipping containers and shipping processes  
33.5 to ensure drug stability and potency. The shipping processes must include the use of  
33.6 appropriate packaging material and devices, according to the recommendations of the  
33.7 manufacturer and the United States Pharmacopeia Chapter 1079, in order to ensure that  
33.8 the drug is kept at appropriate storage temperatures throughout the delivery process to  
33.9 maintain the integrity of the medication;

33.10 (2) use shipping containers that are sealed in a manner to detect evidence  
33.11 of opening or tampering;

33.12 (3) develop and implement policies and procedures to ensure accountability,  
33.13 safe delivery, and compliance with temperature requirements. The policies and procedures  
33.14 must address when drugs do not arrive at their destination in a timely manner or when  
33.15 there is evidence that the integrity of a drug has been compromised during shipment. In  
33.16 these instances, the pharmacy must make provisions for the replacement of the drugs; and

33.17 (4) provide for an electronic, telephonic, or written communication  
33.18 mechanism for a pharmacist, or a pharmacy intern working under the direct supervision of  
33.19 a pharmacist, to offer counseling to the patient, unless the patient refuses the consultation.  
33.20 Refusal of consultation by patients must be documented. The patient must receive  
33.21 information indicating what the patient should do if the integrity of the packaging or  
33.22 medication has been compromised during shipment.

33.23 C. Adulteration. A drug is adulterated if it has been exposed to conditions of  
33.24 fire, water, or extreme temperature, which may have rendered it injurious to health.

33.25 Subp. 2. **Fax machines.** ~~Prescriptions and~~ Prescription drug orders may be  
33.26 transmitted to a pharmacy via the use of a fax machine only in accordance with this

34.1 subpart and as permitted by law. For a pharmacy other than a hospital pharmacy that is  
34.2 transmitting solely within the institution, the procedures must provide for the identification  
34.3 of the person sending the prescription ~~or~~ drug order. Unless the fax transmission is  
34.4 received on a machine generating a copy that is readily readable for at least five years, all  
34.5 fax transmissions of prescription drug orders shall be followed up within 72 hours with  
34.6 the original hard copy of the order or the pharmacist shall reduce the order received by  
34.7 fax to writing that is of permanent quality. ~~Orders~~ Prescription drug orders for Schedule  
34.8 II-IV controlled substances received by fax shall be handled according to the rules of the  
34.9 federal Drug Enforcement Administration. Prescriptions faxed to the pharmacy by the  
34.10 patient are not to be filled or dispensed.

34.11 Subp. 3. **Electronic prescriptions.** Any electronic prescription transmitted from  
34.12 the prescriber to the pharmacy must comply with Minnesota Statutes, chapter 325L,  
34.13 Minnesota Statutes, section 62J.497, and any applicable rules. Electronic prescriptions for  
34.14 controlled substance drugs must conform to the rules of the federal Drug Enforcement  
34.15 Administration. Except for prescription drug orders for drugs to be administered in an  
34.16 acute care hospital, an electronically transmitted prescription shall be transmitted only to  
34.17 the pharmacy of the patient's choice. ~~This requirement shall not apply to orders for the~~  
34.18 ~~medications to be administered in an acute care hospital.~~

34.19 Subp. 4. **Answering machines and electronic voice recording devices.** Only a  
34.20 practitioner or a practitioner's agent may transmit a prescription to a pharmacy's answering  
34.21 machine or electronic voice recording device. Prescriptions transmitted to a pharmacy's  
34.22 answering machine or an electronic voice recording device shall only be retrieved by a  
34.23 licensed pharmacist or registered pharmacist-intern working under the immediate and  
34.24 direct supervision of a pharmacist. A technician may not retrieve a prescription from these  
34.25 devices, except in the case where the practitioner or authorized agent of the practitioner is  
34.26 approving additional refills of a prescription previously dispensed from the pharmacy and  
34.27 no other changes are made to the prescription. Personnel used for clerical duties according

35.1 to part 6800.3850, subpart 7, may not retrieve any prescription information from these  
 35.2 devices. Prescriptions retrieved from these devices are considered verbal prescription  
 35.3 drug orders that must be reduced to writing and are subject to the requirements of part  
 35.4 6800.3100, subpart 1.

35.5 **6800.3100 COMPOUNDING AND DISPENSING.**

35.6 Subpart 1. **Duties.** The practice of compounding and dispensing a prescription drug  
 35.7 order includes, but is not limited to, the following acts, which shall be performed only by  
 35.8 a pharmacist, practitioner, or pharmacist-intern under the immediate and ~~personal~~ direct  
 35.9 supervision of a pharmacist:

35.10 A. ~~determination~~ determination of brands and suppliers;

35.11 B. ~~receipt of verbal prescriptions~~ prescription drug orders which must  
 35.12 include documentation of the individual communicating the order and the pharmacist  
 35.13 or pharmacist intern receiving the order;

35.14 C. ~~verifying~~ verification of the prescription drug order;

35.15 D. ~~selecting~~ selection of the drug to be used in filling the prescription drug order;

35.16 E. ~~extemporaneous compounding on an individual basis~~ establishment and  
 35.17 validation of the initial formulation record of all compounded preparations according  
 35.18 to part 6800.3300;

35.19 F. ~~eertifying~~ certification of the completed filled prescription drug order;

35.20 G. ~~assuring~~ ensuring that, when required by law or by the best professional  
 35.21 practice, permission to refill is obtained from authorized ~~prescribers or their agents~~  
 35.22 practitioners or other individuals allowed to prescribe legend drugs according to  
 35.23 Minnesota Statutes, section 151.37, subdivision 2, and then noting on the reverse side of  
 35.24 the prescription drug order or in the electronically maintained record of the prescription  
 35.25 drug order the following data: date refilled; name of practitioner or other authorized

36.1 prescriber personally authorizing the refill, and the name of the practitioner's agent  
36.2 transmitting or communicating the refill authorization, if applicable; quantity of drug  
36.3 dispensed, if different from the original prescription; and ~~initials~~ the unique identifier of  
36.4 the pharmacist refilling the prescription;

36.5 H. supervising clerical personnel in limited nonprofessional duties such as  
36.6 looking up prescription refills, filing prescriptions, record keeping, nonprofessional  
36.7 aspects of presenting completed medications to patients, and completing the transaction  
36.8 typing that does not involve prescription data entry, record keeping, filing, and completing  
36.9 sales transactions; and

36.10 I. supervising pharmacy technicians utilized in the performance of certain  
36.11 pharmacy tasks not requiring professional judgment in accordance with part 6800.3850.

36.12 Subp. 2. **Verification.** Verification of validity and propriety under subpart 1, item  
36.13 C, must be of the original prescription drug order. A rewritten, verbal, or electronically  
36.14 produced copy, ~~rewritten, verbal, or electronically produced~~, is not acceptable except as  
36.15 provided in parts 6800.3000, subpart 2, 6800.3120, subpart 7, and 6800.3950, subpart 1a.

36.16 Subp. 3. **Certification.** In certifying and documenting the ~~completed~~ filled  
36.17 prescription drug order under subpart 1, item F, ~~the~~ an individual pharmacist, practitioner,  
36.18 or pharmacist-intern shall ~~include~~:

36.19 A. ~~checking of~~ check the original labeled container from which the medication  
36.20 was withdrawn, ~~except as provided in part 6800.2600;~~

36.21 B. ~~checking of~~ check the labeling on the ~~prescription~~ medication container that  
36.22 will be dispensed;

36.23 C. ~~checking~~ check the contents of the ~~prescription~~ medication container that  
36.24 will be dispensed and the appearance of the total product;

37.1 D. ~~reviewing~~ review the patient's medication profile for purposes of conducting  
37.2 a prospective drug review and checking the accuracy of the addition to the profile of the  
37.3 medication dispensed; and

37.4 E. ~~initialing of~~ place the pharmacist's, practitioner's, or pharmacist-intern's  
37.5 unique identifier on the prescription drug order or other permanently maintained record by  
37.6 ~~the individual performing the certification~~. Those pharmacists using automated medication  
37.7 management dispensing systems must develop written policies and procedures which  
37.8 provide that all certification steps are performed and documented before the medication is  
37.9 ~~distributed~~ dispensed to the patient. These policies and procedures must be made available  
37.10 for inspection by the board upon request.

37.11 Subp. 3a. **Accountability.** ~~The prescription filling process must provide~~  
37.12 ~~documentation to identify the names, initials, or identification codes of each pharmacist,~~  
37.13 ~~pharmacist intern, or pharmacy technician who performed any portion of the prescription~~  
37.14 ~~filling process.~~ For prescriptions filled in a pharmacy, the unique identifier of each  
37.15 pharmacist, pharmacist-intern, or pharmacy technician who performs any portion of the  
37.16 prescription filling process must be documented, with the documentation maintained for a  
37.17 minimum of two years. The documentation must indicate which portion of the prescription  
37.18 filling process each pharmacist, pharmacist-intern, or pharmacy technician completed. For  
37.19 prescriptions filled by a practitioner, the unique identifier of each practitioner and each  
37.20 individual who assists the practitioner according to part 6800.9952 must be documented  
37.21 and the documentation maintained for a minimum of two years. This subpart does not  
37.22 waive the requirement for an individual pharmacist, practitioner, or pharmacist-intern to  
37.23 certify a filled prescription drug order according to subpart 3.

37.24 Subp. 3b. **Notice required.** A pharmacy utilizing a central service pharmacy to  
37.25 provide dispensing functions, drug utilization review, packaging, labeling, delivery of a

38.1 filled prescription product, or other services must notify the pharmacy's patients of that  
38.2 fact.

38.3 [For text of subp 4, see M.R.]

38.4 **6800.3110 PATIENT MEDICATION PROFILES.**

38.5 Subpart 1. **System required.** A patient profile record system must be maintained  
38.6 in all pharmacies for persons for whom ~~prescriptions~~ filled prescription drug orders are  
38.7 dispensed. The patient profile record system must be designed for the immediate retrieval  
38.8 of information necessary for the dispensing pharmacist to identify previously dispensed  
38.9 medication at the time a prescription drug order is presented for dispensing. One profile  
38.10 record may be maintained for all members of a family living at the same address and  
38.11 possessing the same family name.

38.12 [For text of subps 2 and 2a, see M.R.]

38.13 Subp. 3. **Drug interactions, generally.** Upon receiving a prescription drug order, a  
38.14 pharmacist shall examine the patient's profile record before dispensing the medication to  
38.15 determine the possibility of a harmful drug interaction or reaction.

38.16 Upon recognizing a potentially harmful interaction or reaction, the pharmacist shall  
38.17 take appropriate steps to avoid or resolve the problem which shall, if necessary, include  
38.18 consultation with the prescriber.

38.19 Subp. 4. **Drug use review for patients.** Upon receiving a prescription, ~~prescription~~  
38.20 drug order, or prescription refill request for a patient, a pharmacist shall examine the  
38.21 patient's profile record and conduct a prospective drug review to identify:

38.22 [For text of items A to F, see M.R.]

38.23 G. clinical abuse or misuse.

39.1 Upon recognizing any of these drug-related problems, the pharmacist shall take  
39.2 appropriate steps to avoid or resolve the problem which shall, if necessary, include  
39.3 consultation with the prescriber.

39.4 For the purpose of meeting the requirements of this subpart, a pharmacist may rely  
39.5 on computerized medication profile review, provided that it includes all medication  
39.6 dispensed by the pharmacy for the patient during at least the preceding six months. The  
39.7 ~~review must scan all prescriptions received by the patient at the pharmacy during the~~  
39.8 ~~previous six months and conduct the prospective review required in this subpart.~~ The  
39.9 pharmacist-in-charge must develop procedures ~~restricting "override" decision making~~  
39.10 ~~regarding computer-identified drug problems at the pharmacy~~ for handling alerts generated  
39.11 by the computerized medication profile review and include these procedures in the written  
39.12 procedures required under part 6800.3950. Only a pharmacist or a pharmacist-intern  
39.13 working under the immediate and direct supervision of a pharmacist may override the  
39.14 alerts.

39.15 [For text of subp 5, see M.R.]

39.16 Subp. 6. [See repealer.]

39.17 **6800.3120 TRANSFER OF PRESCRIPTIONS BETWEEN PHARMACIES.**

39.18 Subpart 1. **Label, copy, or report.** A prescription label, a written copy of the  
39.19 prescription, or a telephone report of a prescription from another pharmacy may be used  
39.20 for informational purposes only and has no legal status as a valid prescription drug  
39.21 order. A pharmacist who receives a label, copy, or report of a prescription from another  
39.22 pharmacist shall either contact the prescribing practitioner for authorization to dispense  
39.23 the prescription or shall comply with subparts 2 to 6.

39.24 Subp. 2. **Conditions of transfer.** A pharmacy may transfer prescription drug order  
39.25 information for the purpose of refilling a prescription if the information is communicated  
39.26 directly by one licensed pharmacist or registered intern to another licensed pharmacist

40.1 or registered intern. A pharmacy may transfer prescription drug order information for  
40.2 the purpose of the initial filling of the order only according to subpart 8a. Schedule  
40.3 II prescriptions prescription drug orders may not be transferred. Schedules III-V  
40.4 prescriptions prescription drug orders may be transferred in accordance with the  
40.5 limitations placed on such transfers by the Drug Enforcement Administration (DEA).

40.6 Subp. 3. **Duties of transferring pharmacist or intern.** The transferring pharmacist  
40.7 or intern shall:

40.8 A. write the word "VOID" across the face of the current prescription drug order  
40.9 to make the prescription it invalid or, if records are electronically maintained, void all  
40.10 remaining refills previously authorized and carried in the electronic record;

40.11 B. record on the reverse side of the invalidated prescription drug order or in the  
40.12 electronically maintained record of the prescription drug order the name and, address, and  
40.13 telephone number of the receiving pharmacy and the name of the receiving pharmacist  
40.14 or intern; and

40.15 C. record the date of the transfer.

40.16 Recording of prescription drug order transfers by cancellation of the electronic  
40.17 version of the prescription drug order is acceptable only when the quality assurance check  
40.18 required by part 6800.3950, subpart 4, has been completed on the prescription drug  
40.19 order being transferred.

40.20 For controlled substances in Schedules III-V, parts 6800.4230 to 6800.4250, the  
40.21 transferring pharmacist or intern shall also record on the reverse side of the invalidated  
40.22 prescription drug order or in the electronically maintained record of the prescription  
40.23 drug order, the Drug Enforcement Administration registration number of the receiving  
40.24 pharmacy and the names of the receiving and transferring pharmacists or interns.

40.25 Subp. 4. **Duties of receiving pharmacist or intern.** The pharmacist or intern  
40.26 receiving the transferred prescription drug order information shall write the word



41.1 "transfer," "copy," or a word of similar import on the face of the transferred prescription,  
41.2 and shall ~~provide~~ obtain from the transferring pharmacist or intern all information required  
41.3 by law to be on a prescription, ~~including plus~~:

41.4 [For text of items A to E, see M.R.]

41.5 F. the transferring pharmacy's name ~~and~~, address, and telephone number and, ~~in~~  
41.6 ~~the case of a controlled substance in Schedules III-V, parts 6800.4230 to 6800.4250, the~~  
41.7 ~~transferring pharmacy's Drug Enforcement Administration registration number and the~~  
41.8 ~~name of the~~ transferring pharmacist or intern. In the case of a controlled substance listed  
41.9 in Schedules III-V, parts 6800.4230 to 6800.4250, the receiving pharmacist or intern must  
41.10 obtain the transferring pharmacy's Drug Enforcement Administration registration number.

41.11 Subp. 5. **Retention of prescription.** The transferring ~~pharmacist~~ pharmacy shall  
41.12 keep the original prescription drug order on file for at least two years from the date of last  
41.13 filling. The receiving ~~pharmacist~~ pharmacy shall keep the transferred prescription drug  
41.14 order on file for at least two years from the date of last filling.

41.15 [For text of subp 6, see M.R.]

41.16 Subp. 7. **Computerized prescription record keeping system.** A computerized  
41.17 prescription record keeping system must satisfy all the requirements of subparts 2 to 6  
41.18 including invalidation of the original prescription drug order. Pharmacies accessing a  
41.19 common electronic file or data base used to maintain required dispensing information  
41.20 are not required to transfer ~~prescriptions~~ prescription drug orders or information for  
41.21 dispensing purposes between or among pharmacies participating in the same common  
41.22 prescription file or data base; provided, however, that any such common file or database  
41.23 must contain complete records of each prescription drug order and refill dispensed and  
41.24 further, that a hard copy record of each prescription drug order transferred or accessed  
41.25 for purposes of refilling must be generated and maintained at the pharmacy refilling the  
41.26 prescription or to which the prescription has been transferred.

42.1 Subp. 8. **Transfer of prescription drug order.** Except as provided in subpart 7,  
42.2 when the transfer of original prescription drug order information is initiated by the receipt  
42.3 of a prescription container previously filled at another pharmacy, the receiving pharmacist  
42.4 shall notify the transferring pharmacist that the prescription is being transferred. All  
42.5 information required by subparts 2 to 6 must be exchanged.

42.6 Subp. 8a. **Transfer of nondispensed drug orders.** Prescription drug orders that are  
42.7 entered into a computer system but never dispensed to the patient may be transferred to  
42.8 another pharmacy if all of the following conditions are met:

42.9 A. all prescription drug order information has been entered into the computer  
42.10 system of the transferring pharmacy;

42.11 B. the information is displayed on the patient's profile in a manner that indicates  
42.12 the prescription drug order was not filled at the transferring pharmacy;

42.13 C. there is present, either in the computer system or on the hard copy  
42.14 prescription drug order, the unique identifier of the person who entered the prescription  
42.15 drug order information into the system and of the pharmacist who certified this entry, and  
42.16 of the pharmacist who performed the quality assurance verification as required by part  
42.17 6800.3950, subpart 4. If the quality assurance verification has not occurred, then the  
42.18 prescription information exchanged must be from the original written prescription drug  
42.19 order;

42.20 D. the original prescription drug order is kept on record according to Minnesota  
42.21 Statutes, section 151.211; and

42.22 E. all other requirements of this part are met.

42.23 Subp. 9. **Unprofessional conduct.** The board shall consider it evidence of  
42.24 unprofessional conduct to reveal to others the nature of professional pharmaceutical  
42.25 services rendered to a patient without the express oral or written consent of the patient or

43.1 without an order or direction of a court. A ~~pharmacy~~ pharmacist or a pharmacist intern  
43.2 ~~may, however,~~ provide informational copies of a prescription drug order to another  
43.3 ~~pharmacy~~ pharmacist or pharmacist intern who is currently providing services to or  
43.4 acting at the request of the patient, as provided in this part; or to the person to for whom  
43.5 the prescription drug order was issued as provided in this part. A pharmacist may also  
43.6 provide drug therapy information to a physician ~~for~~ or other licensed, registered, or  
43.7 certified health care professional who is currently providing services to or acting on the  
43.8 behalf of the patient.

43.9 The board shall consider it evidence of unprofessional conduct for a pharmacist to  
43.10 refuse to provide a transfer of original prescription drug order information to another  
43.11 pharmacist who is acting on behalf of a patient and who is making a legal request for  
43.12 this information under this part.

43.13 Subp. 10. **Schedule II controlled substances.** Nothing in this part authorizes  
43.14 the transfer of a prescription drug order for a Schedule II controlled substance. ~~A new~~  
43.15 ~~written prescription personally signed by the prescribing practitioner is required prior to~~  
43.16 ~~dispensing a Schedule II controlled substance.~~ All prescription drug orders for Schedule  
43.17 II controlled substances must conform to the requirements of the federal Controlled  
43.18 Substances Act and to the regulations of the Drug Enforcement Administration.

43.19 Subp. 11. **Shared information.** Prescription drug order information shared between  
43.20 two pharmacies which are accessing the same real-time, online database, according to  
43.21 the operation of a board-approved central service operation shall not be considered a  
43.22 prescription copy and is not subject to the requirements of this part.

#### 43.23 **6800.3200 PREPACKAGING AND LABELING.**

43.24 Subpart 1. **Prepackaging.** Pharmacies may prepackage and label drugs in convenient  
43.25 quantities for subsequent complete labeling and dispensing according to United States  
43.26 Pharmacopeia, chapter 1146. Such drugs shall be prepackaged by or under the direct

44.1 supervision of a pharmacist. The supervising pharmacist shall cause to be prepared and  
44.2 kept a packaging control record containing the following information:

44.3 A. date;

44.4 B. identification of drug: name, dosage form, manufacturer or distributor,  
44.5 ~~manufacturer's~~ lot number assigned by manufacturer or distributor, strength, and  
44.6 ~~manufacturer's~~ expiration date assigned by manufacturer or distributor, if any;

44.7 C. container specification;

44.8 D. copy of the label;

44.9 E. ~~initials~~ unique identifier of the packager;

44.10 F. ~~initials~~ unique identifier of the supervising pharmacist;

44.11 G. quantity per container; and

44.12 H. internal control number or date.

44.13 Subp. 2. **Labeling.** Each prepackaged container shall bear a label containing the  
44.14 following information:

44.15 [For text of items A to D, see M.R.]

44.16 E. internal control number or date; ~~and~~

44.17 F. after July 1, 2008, a physical description, including any identification code  
44.18 that may appear on tablets and capsules or a bar code based on the National Drug Code  
44.19 (NDC). Such a description does not need to be placed on individual unit-doses, provided  
44.20 that the pharmacy dispenses the unit-doses in outer packaging that contains a physical  
44.21 description of the drug or the pharmacy dispenses less than a 72-hour supply of the  
44.22 unit-doses; and

44.23 G. radiopharmaceuticals must be labeled according to the requirements of  
44.24 part 6800.8550.

45.1 **6800.3300 COMPOUNDING STANDARDS.**

45.2 [For text of subps 1 to 5, see M.R.]

45.3 Subp. 6. **Certifying compounding procedure.** A pharmacist shall certify that each  
45.4 component used in the compounding of a drug product has been accurately weighed,  
45.5 measured, or subdivided, as appropriate, at each stage of the compounding procedure in  
45.6 order to verify conformance with the formula being prepared. Subsequent stages of the  
45.7 compounding process may not be completed until this certification occurs.

45.8 **6800.3350 PHARMACEUTICALS BEYOND-USE DATES.**

45.9 [For text of subps 1 to 3, see M.R.]

45.10 Subp. 4. **Prescription vials.** ~~Prescription~~ When a drug is dispensed in a prescription  
45.11 vial, a beyond-use date need not be printed on the label. Drugs dispensed in prescription  
45.12 vials ~~and~~ that are labeled with a beyond-use date shall bear a beyond-use date of not  
45.13 more than one year from the dispensing date or the time remaining to the manufacturer's  
45.14 expiration date, whichever is less.

45.15 Nothing in this part supersedes the pharmacist's professional judgment.

45.16 **6800.3400 PRESCRIPTION LABELING.**

45.17 Subpart 1. **Requirements applicable to all drugs.** Except for radiopharmaceuticals,  
45.18 all drugs dispensed to or for a patient, other than an inpatient of a hospital ~~shall~~ must be  
45.19 labeled with the following information:

45.20 A. name, address, and telephone number of the pharmacy filling the prescription  
45.21 drug order, except that central service pharmacies shall use the name, address, and  
45.22 telephone number of the pharmacy ~~distributing~~ dispensing the medication to the patient;

45.23 [For text of items B to H, see M.R.]

46.1 I. generic or trade name of drug and strength, except when specified by  
46.2 prescriber to the contrary. In the case of combining premanufactured drug products, the

46.3 names of the products, or a category of use name shall suffice. In the case of compounding  
 46.4 basic pharmaceutical ingredients, the common pharmaceutical name, if such exists, the  
 46.5 names and strengths of the principle active ingredients or a category of use ~~label~~ name  
 46.6 shall suffice;

46.7 J. ~~prescriptions~~ prescription drug orders filled as part of a central service  
 46.8 operation ~~shall~~ must bear a ~~unique~~ an identifier ~~to indicate that the prescription was filled~~  
 46.9 ~~at a~~ that indicates the central service pharmacy at which they were filled; and

46.10 K. after July 1, 2008, any dispensed ~~prescription medication~~ shall legend  
 46.11 drug, or nonlegend drug not dispensed in the manufacturer's original container, must be  
 46.12 labeled with its physical description, including any identification code that may appear on  
 46.13 tablets and capsules. This requirement does not apply to drugs dispensed as part of an  
 46.14 investigational drug study.

46.15 [For text of subps 2 and 3, see M.R.]

46.16 Subp. 4. **Veterinary prescription drug label.** ~~A veterinary prescription drug label~~  
 46.17 ~~must include~~ The label for a filled veterinary prescription that is dispensed by a licensed  
 46.18 pharmacy must include:

46.19 A. in the case of non-food-producing animals, the name of the client or animal.  
 46.20 In the case of food-producing animals, the name of the owner and the specific name and  
 46.21 address of the facility at which the filled prescription will be used;

46.22 [For text of items B to G, see M.R.]

46.23 H. cautionary statements if appropriate for the drug; ~~and~~

46.24 I. ~~when the veterinary drug is in the manufacturer's original package and the~~  
 46.25 ~~information that is required on the label includes the drug or drugs, strength of the drug~~  
 47.1 ~~or drugs, directions for use, withdrawal time for food-producing animals, and cautionary~~  
 47.2 ~~statements, a label will be required on each individual bottle or package.~~ the name,

47.3 address, and telephone number of the pharmacy, except that central service pharmacies  
47.4 must use the name, address, and telephone number of the pharmacy dispensing the  
47.5 medication to the client;

47.6 J. the name and address of the prescribing veterinarian, except that the  
47.7 address of the prescribing veterinarian is not required if the prescription is for a  
47.8 non-food-producing animal; and

47.9 K. the prescription number.

47.10 When the veterinary drug is in the manufacturer's original package and the information  
47.11 that is required on the label includes the drug or drugs, strength of the drug or drugs,  
47.12 directions for use, withdrawal time for food-producing animals, and cautionary statements,  
47.13 a label will be required on each individual bottle or package.

47.14 Subp. 5. **Radiopharmaceutical labeling.** Radiopharmaceutical labeling shall  
47.15 comply with the requirements in part 6800.8550.

47.16 **6800.3450 LABELING OF OUTPATIENT INTRAVENOUS ADMIXTURE**  
47.17 **DRUGS.**

47.18 [For text of subp 1, see M.R.]

47.19 Subp. 2. **Additions to admixtures.** When an additional drug is added to intravenous  
47.20 admixtures, the admixtures shall be labeled on the original label or with a distinctive  
47.21 supplementary label indicating the name and the amount of the drug added, date and time  
47.22 of addition and expiration, and ~~initials~~ the unique identifier of the person adding the drug.

47.23 [For text of subp 3, see M.R.]

47.24 **6800.3510 REFILL LIMITATIONS.**

48.1 No prescription drug order may be filled or refilled more than 12 months after the  
48.2 date on which ~~the prescription~~ it was issued. Refills originally authorized in excess  
48.3 of 12 months are void 12 months after the original date of issuance of the prescription

48.4 drug order. After 12 months from the date of issuance of a prescription drug order,  
48.5 no additional authorizations may be accepted for that prescription drug order. If the  
48.6 prescriber desires continued therapy, a new prescription drug order must be generated  
48.7 and a new prescription number assigned.

48.8 **6800.3750 UNIT DOSE DISPENSING.**

48.9 [For text of subps 1 and 2, see M.R.]

48.10 Subp. 3. **Unit dose system.** The unit dose system is that drug distribution system  
48.11 which is pharmacy based and which uses unit dose packaging in a manner which removes  
48.12 traditional drug stocks from patient care areas and enables the selection and distribution of  
48.13 unit dose packaging to be pharmacy based and controlled.

48.14 The system must provide and the pharmacist must utilize:

48.15 [For text of items A to C, see M.R.]

48.16 D. a means of identifying the dosage regimen of each drug, including the date  
48.17 of the original prescription drug order and the date of changes, if any, ~~in the prescriber's~~  
48.18 made to the prescription drug order;

48.19 [For text of items E and F, see M.R.]

48.20 G. a means for the pharmacist to verify the original ~~prescriber's~~ prescription  
48.21 drug order; and

48.22 [For text of item H, see M.R.]

48.23 [For text of subps 4 to 8, see M.R.]

48.24 Subp. 9. **Storage of medications.**

49.1 A. ~~All medication shall be stored in a locked area or locked cart.~~ All controlled  
49.2 substances must be stored in a locked area or locked cart at all times.



49.3 B. All noncontrolled substances must be stored in a locked area or locked cart  
49.4 when a patient care area is not staffed. An area in which staff is actively providing patient  
49.5 care or preparing to receive patients is considered a secure area and locked storage of  
49.6 noncontrolled substances is not required.

49.7 [For text of subp 10, see M.R.]

49.8 **6800.3850 PHARMACY TECHNICIANS.**

49.9 Subpart 1. **Technician registration required.** Pharmacy technicians may be used  
49.10 in performing pharmacy tasks not specifically reserved in this chapter to a licensed  
49.11 pharmacist only when the technician is properly registered with the board. An individual  
49.12 may not, under any circumstances, perform pharmacy tasks as a pharmacy technician prior  
49.13 to being registered as a pharmacy technician according to this part. Registration does not  
49.14 include any determination of the competency of the registered individual. ~~Registration is~~  
49.15 ~~established for the purpose of identification, tracking, and disciplinary action.~~

49.16 Subp. 1a. **Denial and suspension of registration.** The board may deny, suspend,  
49.17 revoke, refuse to renew, or place conditions and limitations on the registration of a  
49.18 technician for any violation of the rules of the board or the laws of this state, another  
49.19 state, or the United States relating to the practice of pharmacy, prescription drugs, or  
49.20 controlled substances.

49.21 Subp. 1b. **Registration, renewals.**

49.22 A. A pharmacy technician registration expires each year on December 31 and  
49.23 shall be renewed annually by filing an application for registration renewal on or before  
49.24 December 1 of each year, together with the fee listed in subpart 1c.

50.1 ~~B. For the purposes of implementing this subpart, beginning January 1, 1999, a~~  
50.2 ~~pharmacy technician must register with the board pursuant to the requirements of this part.~~

50.3 ~~€~~ B. Initial registration shall not be prorated.

50.4 Subp. 1c. **Registration fee, late fee.**

50.5 A. The fee for an initial registration is ~~\$15. Effective July 1, 2000, the initial~~  
50.6 ~~registration is \$20~~ is the amount established in Minnesota Statutes, chapter 151.

50.7 B. The fee for each annual renewal is ~~\$15. Effective July 1, 2000, the annual~~  
50.8 ~~renewal is \$20~~ is the amount established in Minnesota Statutes, chapter 151.

50.9 C. The fee must be paid at the time when a new application or a renewal  
50.10 application is submitted to the board.

50.11 D. Persons required to renew their registration under this part, who file an  
50.12 application which is received by the board after the date ~~at~~ on which it is due, must pay a  
50.13 late fee of 50 percent of the renewal fee in addition to the renewal fee.

50.14 [For text of subp 1d, see M.R.]

50.15 Subp. 1e. **Identification of technician.**

50.16 A. A pharmacy technician must wear a name badge while on duty which clearly  
50.17 identifies the person as a "Pharmacy Technician-," except when complying with the  
50.18 requirements of United States Pharmacopeia Chapter 797.

50.19 B. Pharmacy technicians must not represent themselves as pharmacists in any  
50.20 manner.

50.21 [For text of subp 1f, see M.R.]

50.22 Subp. 1g. **Minimum age.** Prior to January 1, 2012, the board shall not register as a  
50.23 pharmacy technician any individual who is less than 16 years of age. Effective January 1,  
50.24 2012, the board shall not register as a pharmacy technician any individual who is less than  
51.1 18 years of age. An individual who is less than 18 years of age and who was registered  
51.2 by the board as a pharmacy technician prior to January 1, 2012, may renew registration  
51.3 provided that all other requirements for renewal are met.

51.4 Subp. 1h. **Education and training requirements.**

51.5 A. **Initial registration.** Effective January 1, 2013, the board shall not issue  
51.6 an initial pharmacy technician registration to any individual who does not present the  
51.7 board with evidence of high school graduation or possession of a general educational  
51.8 development certificate equivalent. An individual who is not a high school graduate or  
51.9 who does not possess a general educational development certificate equivalent who was  
51.10 registered by the board prior to January 1, 2013, may renew the individual's registration  
51.11 provided that all other requirements for renewal are met and provided the individual  
51.12 maintains a pharmacy technician registration on an uninterrupted basis. Any individual  
51.13 whose registration lapses for a period of more than one year must meet the registration  
51.14 requirements in effect at the time the individual applies for reinstatement of registration.

51.15 B. **Renewal of registration.** Effective January 1, 2013, the board shall not  
51.16 renew the registration of a pharmacy technician who was initially registered after January  
51.17 1, 2012, or who was initially registered prior to that date but did not maintain continuous  
51.18 registration, unless the individual provides the board with evidence of completion of  
51.19 one of the following:

51.20 (1) a pharmacy technician training program offered by a board-approved,  
51.21 accredited vocational/technical institution or college;

51.22 (2) a pharmacy technician training program accredited by a board-approved,  
51.23 national organization that accredits pharmacy technician training programs;

51.24 (3) a pharmacy technician training program provided by a branch of the  
51.25 United States armed forces or Public Health Service; or

52.1 (4) an employer-based pharmacy technician training program that includes  
52.2 a minimum total of 480 hours on a one-year period to include both theoretical and  
52.3 practical instruction. An employer utilizing such a program must develop and regularly  
52.4 update a technician training manual that must be available for board inspection upon

52.5 request. The employer must also supply a technician who completes the training program  
52.6 with written evidence of completion. The employer-based pharmacy technician training  
52.7 program must include written guidelines, policies, and procedures that define the specific  
52.8 tasks the technician will be expected to perform. The board may renew the registration of  
52.9 a pharmacy technician who has not completed this training requirement provided that:  
52.10 less than six months has elapsed between the date of initial registration as a pharmacy  
52.11 technician and the date of the pharmacy technician's first renewal of registration; or  
52.12 the pharmacy technician shows satisfactory evidence of being enrolled in a pharmacy  
52.13 technician training program offered by a board-approved, accredited vocational/technical  
52.14 institution or college, when the program is longer than six months in length.

52.15 C. **Pharmacy-specific training.** Notwithstanding the fact that a technician  
52.16 has completed a training program as specified in item B, it is the responsibility of the  
52.17 pharmacist-in-charge of a pharmacy to ensure that a technician receives adequate training  
52.18 in the tasks performed by technicians working at that pharmacy.

52.19 Subp. 2. **Permissible duties.** Pharmacy technicians may perform ~~technician~~  
52.20 ~~functions which~~ pharmacy tasks not specifically reserved in this chapter to a licensed  
52.21 pharmacist or pharmacist-intern and that do not involve the use of professional  
52.22 pharmaceutical judgment.

52.23 Subp. 3. **Certifying.** Pharmaceutical products prepared or processed, in whole or in  
52.24 part, by a pharmacy technician must be certified for accuracy by a licensed pharmacist,  
52.25 practitioner, or pharmacist-intern as provided for in part 6800.3100, subpart 1, item F,  
52.26 prior to release for patient use.

53.1 Subp. 4. **Written procedures.** Written procedures for the use of pharmacy  
53.2 technicians in a pharmacy shall be prepared by the pharmacist-in-charge. A copy of  
53.3 the procedures must be given to each technician and a copy must be kept on file in the  
53.4 pharmacy. The written procedures must be made available for inspection by the board

53.5 upon request. These procedures must comply with the standards in this chapter and will  
53.6 be reviewed for compliance on that basis.

53.7 These procedures must indicate in detail the tasks performed by the pharmacy  
53.8 technician; the name, address, and registration number of the pharmacy technician; and  
53.9 the certification steps performed by the licensed pharmacist in verifying the technician's  
53.10 work. Procedures ~~shall~~ must be updated at least every five years; and whenever a  
53.11 significant change in the way in which pharmacy technicians are utilized occurs. The  
53.12 pharmacist-in-charge shall document that each technician reviews the procedures when  
53.13 the technician is first employed by the pharmacy as a technician, when any substantial  
53.14 changes to the procedures have been made, and at least annually.

53.15 Subp. 5. **Supervision.** Pharmacy technicians shall be supervised by a licensed  
53.16 pharmacist, ~~practitioner, or pharmacist intern~~ stationed within the same work area who  
53.17 has the ability to control and is responsible for the action of the pharmacy technician. The  
53.18 ultimate responsibility for the actions of a pharmacy technician working under a licensed  
53.19 pharmacist's supervision shall remain with the licensed pharmacist.

53.20 Subp. 6. **Ratios.** The basic ratio of pharmacy technicians to pharmacists on duty  
53.21 in a pharmacy is two technicians to one pharmacist. Specific functions are excepted  
53.22 from the basic ratio as follows:

53.23 [For text of items A to C, see M.R.]

53.24 D. ~~bulk~~ compounding (part 6800.3300), 3:1.  
53.25 The most restrictive ratio shall apply in a pharmacy in which multiple functions are being  
53.26 performed.

54.1 Subp. 7. **Persons not included.** Personnel used solely for clerical duties such as  
54.2 typing, ~~other than prescription~~ or keyboarding that does not involve prescription data  
54.3 entry, and record keeping, filing, billing, and completing sales transactions need not  
54.4 be included ~~in the ratios of the functions performed by pharmacy technicians~~ when

54.5 determining compliance with the ratios listed in this part. Personnel used solely for  
54.6 the delivery of filled prescription drug orders need not be included when determining  
54.7 compliance with the ratios listed in this part.

54.8 A pharmacist-intern submitting hours toward completion of the ~~1,500-hour~~  
54.9 1,600-hour requirement is not considered a pharmacy technician for the purpose of  
54.10 determining the number of pharmacy technicians supervised by a licensed pharmacist.

54.11 Subp. 8. [Repealed, 23 SR 1597]

54.12 Subp. 9. ~~Penalty~~ **Unprofessional conduct.** The use of pharmacy technicians in the  
54.13 performance of delegated tasks not included in written procedures may be considered  
54.14 ~~to be~~ unprofessional conduct on the part of the pharmacist supervising the technician,  
54.15 the pharmacist-in-charge, and the pharmacy technician. Falsification of any documents  
54.16 pertaining to the training of pharmacy technicians shall be considered unprofessional  
54.17 conduct on the part of any pharmacist or pharmacy technician involved in such act.

54.18 **6800.3950 ELECTRONIC DATA PROCESSING; COMPUTER USAGE.**

54.19 Subpart 1. **Policy and procedures.** Up-to-date written policy and procedures shall  
54.20 be developed and maintained that explain the operational aspects of the ~~automated~~  
54.21 electronic data processing system and shall:

54.22 A. include examples of output documentation provided by the ~~automated~~  
54.23 electronic data processing system that pertain to dispensing or drug control records;

54.24 B. outline steps to be followed when the ~~automated~~ electronic data processing  
54.25 system is not operational due to scheduled or unscheduled system interruption;

55.1 [For text of items C and D, see M.R.]

55.2 Subp. 1a. **Entering prescription drug orders.** When electronic data processing  
55.3 equipment is employed by any pharmacy, input of drug information may be performed by  
55.4 a prescriber or a pharmacist. If prescription drug orders are entered by other personnel,

55.5 the pharmacist or the prescriber; must certify the accuracy of the information entered and  
55.6 verify the prescription drug order prior to the dispensing of the medication. The ~~identity~~  
55.7 unique identifier of the person entering the prescription drug order must be retained in  
55.8 the computer record.

55.9 Subp. 2. **Minimum requirements.** Electronic data processing equipment, when  
55.10 used to store prescription information, must:

55.11 [For text of items A and B, see M.R.]

55.12 C. guarantee the confidentiality of the information contained in the ~~data bank~~  
55.13 system's storage devices and databases;

55.14 D. produce a hard copy daily summary of controlled substance transactions and  
55.15 be capable of producing a hard copy printout of legend drug transactions going back  
55.16 two years, except that if this information is already available in hard copy form it is not  
55.17 necessary to duplicate the data through a computer-generated hard copy;

55.18 E. be capable of recording and carrying in the record all dates of refills of any  
55.19 prescription drug order and ~~initials~~ the unique identifier of the pharmacist ~~which shall act~~  
55.20 in lieu of the requirements of part 6800.3100, subpart 1, item G (initials);

55.21 F. be capable of producing a patient profile indicating all drugs being taken and  
55.22 the dates and quantities of fills or refills of these prescriptions prescription drug orders  
55.23 dispensed for the patient and;

55.24 [For text of subitems (1) and (2), see M.R.]

56.1 G. be capable of being reconstructed in the event of a computer malfunction or  
56.2 accident resulting in destruction of the ~~data bank~~ system's storage devices or databases;

56.3 H. be capable of producing a printout providing a refill-by-refill audit trail for  
56.4 any specified strength and dosage form of any controlled substance. The audit trail must  
56.5 include the name of prescribing practitioner, the name and location of patient, the quantity

56.6 dispensed on each refill, the date of dispensing of each refill, the name or ~~identification~~  
56.7 ~~code~~ unique identifier of the dispensing pharmacist, and the prescription number;

56.8 I. be capable of identifying any authorized changes in drug, quantity, or  
56.9 directions for use of any prescription drug order including the date of change, the  
56.10 identity or unique identifier of the individual making the change, and what the original  
56.11 information was; alternatively a new prescription drug order may be created for each  
56.12 authorized change; and

56.13 J. be capable of preventing unauthorized access, modification, or manipulation  
56.14 of patient prescription data.

56.15 [For text of subp 3, see M.R.]

56.16 Subp. 4. **New prescriptions.**

56.17 A. A pharmacy must develop and implement a written quality assurance plan  
56.18 that includes ~~the~~ a pharmacist, or a pharmacist-intern working under the immediate and  
56.19 direct supervision of a pharmacist, comparing the original written prescription or an image  
56.20 of the original written prescription, to the information entered into the computer, and  
56.21 documenting the completion and accuracy of this comparison with the date and ~~initials~~  
56.22 unique identifier of the pharmacist or pharmacist-intern completing the task. This process  
56.23 must not occur prior to two hours after the prescription has been initially certified, unless  
56.24 it is completed by a second individual pharmacist as soon as possible after the initial  
56.25 certification has occurred. The process must be completed within 72 hours.

57.1 [For text of item B, see M.R.]

57.2 [For text of subps 5 and 6, see M.R.]

57.3 **6800.4075 CENTRALIZED PRESCRIPTION PROCESSING AND FILLING.**

57.4 [For text of subp 1, see M.R.]

57.5 Subp. 2. **Requirements; policy and procedures.**



57.6 A. A pharmacy may perform or outsource centralized prescription drug order  
57.7 filling or centralized prescription drug order processing services provided:

57.8 [For text of subitems (1) to (3), see M.R.]

57.9 (4) the parties provide the board with a copy of the policy and procedures  
57.10 manual described in item B at least 30 days before centralized prescription drug order  
57.11 processing services begin.

57.12 B. The parties performing or contracting for centralized prescription drug order  
57.13 processing services shall maintain a policy and procedures manual and documentation  
57.14 that operations are occurring in a manner consistent with the manual. The manual shall  
57.15 be made available to the board for review upon request and shall include, at a minimum,  
57.16 the following:

57.17 [For text of subitems (1) to (6), see M.R.]

57.18 **Subp. 3. Certification and counseling.**

57.19 A. A pharmacist or pharmacist intern at the pharmacy that dispenses, delivers,  
57.20 mails, or ships the completed prescription drug order to the patient is responsible for  
57.21 certifying the completed prescription drug order, except as provided for in Minnesota  
57.22 Statutes, section 151.215.

58.1 B. A pharmacist or pharmacist intern at the pharmacy that dispenses, delivers,  
58.2 mails, or ships the completed prescription drug order to the patient is responsible for  
58.3 counseling the patient according to part 6800.0910.

58.4 **Subp. 4. Notification.** A pharmacy utilizing a central service pharmacy to provide  
58.5 dispensing functions, drug utilization review, packaging, labeling, delivery of a completed  
58.6 prescription ~~product~~ drug order, or other services must notify its patients of that fact.

58.7 **6800.4200 INCLUSIONS AND EXCEPTIONS.**

58.8 [For text of subp 1, see M.R.]

58.9 Subp. 2. **Exceptions.** Drugs which are not required by federal law to bear any one  
58.10 of the following symbols, C-I, C-II, C-III, C-IV, or C-V, I, II, III, IV, or V, are exempt  
58.11 from the provisions of Minnesota Statutes, section 152. Provided, however, that drugs  
58.12 containing any quantity of phenobarbital shall be dispensed only ~~on~~ according to a  
58.13 prescription drug order.

58.14 **6800.4300 DISPENSING SCHEDULE II CONTROLLED SUBSTANCES FOR**  
58.15 **PATIENTS IN LONG-TERM CARE FACILITIES AND TERMINALLY ILL**  
58.16 **PATIENTS.**

58.17 Subpart 1. **Authorization.** ~~Prescriptions~~ Prescription drug orders for schedule II  
58.18 controlled substances written for patients in long-term care facilities and terminally ill  
58.19 patients may be dispensed in partial quantities, including individual dosage units.

58.20 Subp. 2. **Records.** For each partial dispensing, the dispensing pharmacist shall record  
58.21 on the back of the prescription drug order, or on another appropriate record uniformly  
58.22 maintained and readily retrievable, the date of the partial dispensing, the quantity  
58.23 dispensed, the remaining quantity authorized to be dispensed, and the ~~identification~~ unique  
58.24 identifier of the dispensing pharmacist. The pharmacist must record on the prescription  
58.25 drug order whether the patient is "terminally ill" or an "LTCF patient."

59.1 [For text of subp 3, see M.R.]

59.2 Subp. 4. **Validity of prescription.** Schedule II ~~prescriptions~~ prescription drug  
59.3 orders for patients in a long-term care facility and terminally ill patients shall be valid  
59.4 for a period not to exceed 60 days from the issue date unless terminated sooner by the  
59.5 discontinuance of medication.

59.6 Subp. 5. **Computerization of information.** Information pertaining to current  
59.7 schedule II ~~prescriptions~~ prescription drug orders for patients in a long-term care facility  
59.8 and terminally ill patients may be maintained in a computerized record keeping system  
59.9 if the system has the capability to permit:

59.10 A. output by display or printout of the original prescription number; date  
 59.11 of issue; identification of prescribing individual practitioner; identification of patient;  
 59.12 identification of long-term care facility; identification of medication authorized, including  
 59.13 dosage form, strength, and quantity; listing of partial dispensings that have been dispensed  
 59.14 under each prescription drug order; and the information required in subpart 2;

59.15 B. immediate or real time updating of the prescription drug order record each  
 59.16 time a partial dispensing of the prescription is conducted; and

59.17 C. retrieval of partially dispensed schedule II prescription drug order  
 59.18 information, the same as required by federal law for schedule III and IV prescription  
 59.19 refill information.

59.20 **6800.5100 DEFINITIONS.**

59.21 Subpart 1. [See repealer.]

59.22 Subp. 2. ~~Approved externship~~ **Experiential education program.** "Approved  
 59.23 externship program" means an undergraduate program of practical experience  
 59.24 administered by a college of pharmacy approved by the board. "Experiential education  
 60.1 program" means the pharmacy practice experience component of the professional  
 60.2 pharmacy curriculum of an accredited college or school of pharmacy.

60.3 Subp. 3. **Concurrent time internship.** "Concurrent time internship" means  
 60.4 internship experience gained during the ~~fourth, fifth, and sixth academic~~ second, third, and  
 60.5 fourth professional academic years only, while a person is a full-time student carrying, in  
 60.6 any given school term, 12 or more credits.

60.7 [For text of subp 4, see M.R.]

60.8 Subp. 5. **Pharmacist-intern; intern.** "Pharmacist-intern" and "intern" mean:

60.9 [For text of items A to C, see M.R.]

60.10 D. a participant in a residency or fellowship program, not licensed to practice  
60.11 pharmacy in the state of Minnesota, who is a licensed pharmacist in another state or who  
60.12 is a graduate of the University of Minnesota College of Pharmacy or another pharmacy  
60.13 college approved by the board.

60.14 Subp. 6. **Preceptor.** "Preceptor" means a natural person licensed as a pharmacist  
60.15 by the Board of Pharmacy, or a licensed pharmacist working in a federal health care  
60.16 facility, who participates in instructional programs approved by the board and is providing  
60.17 instruction and direction to pharmacist-interns related to their practical experience.

60.18 Subp. 7. [See repealer.]

60.19 Subp. 8. [See repealer.]

60.20 Subp. 9. [See repealer.]

60.21 Subp. 10. [See repealer.]

## 60.22 **6800.5300 REGISTRATION AND REPORTING.**

60.23 Subpart 1. **Registration.** Every person shall register with the board before  
60.24 beginning ~~an a pharmacy internship, residency, or fellowship~~ in Minnesota. Every person  
61.1 participating in a pharmacy residency or fellowship shall either register as an intern or be  
61.2 licensed as a pharmacist. Applications for the registration of a pharmacist-intern shall be  
61.3 on a form or forms the Board of Pharmacy prescribes and shall be accompanied by a fee of  
61.4 ~~\$20~~ established in Minnesota Statutes, chapter 151. Registration remains in effect ~~during~~  
61.5 ~~successive quarters of internship training~~ if notices of employment, progress reports,  
61.6 examinations, and report affidavits of experience, or similar forms are submitted as  
61.7 required by the board are submitted promptly upon beginning or terminating employment,  
61.8 and if the board is satisfied that the registrant is in good faith and with reasonable diligence  
61.9 pursuing a degree in pharmacy, is a qualified applicant awaiting an examination for  
61.10 licensure, or is completing a pharmacy residency or fellowship. Registration as an intern

61.11 for purposes of participating in a residency or fellowship program remains in effect until  
61.12 the individual obtains licensure as a pharmacist, for two years, or until the completion of  
61.13 the residency or fellowship program, whichever occurs first. Credit for internship ~~time~~  
61.14 hours will not be granted unless registration forms and materials, notices of employment,  
61.15 and progress reports, and report affidavits of experience for preceding time are completed  
61.16 and received are submitted as required by the board.

61.17 Subp. 2. **Identification.** The pharmacist-intern shall be so designated in professional  
61.18 relationships, and shall in no manner falsely assume, directly or by inference, to be a  
61.19 pharmacist. The board shall on proper registration issue to the intern a pocket registration  
61.20 card for purposes of identification and verification of the intern's ~~role as an intern, and~~  
61.21 ~~the card shall be surrendered to the director of the board on termination of the internship~~  
61.22 program registration.

61.23 [For text of subp 3, see M.R.]

61.24 Subp. 4. [See repealer.]

61.25 Subp. 5. **Manual.** Interns completing ~~240~~ 400 hours or more of their internship  
61.26 requirement in Minnesota must complete an internship manual, provided by the board,  
62.1 before the board will recognize the completed hours as acceptable for use in meeting the  
62.2 board's internship requirement.

62.3 Subp. 6. **Termination.** No person who terminates efforts toward the completion of  
62.4 the educational or other prerequisites of licensure, or of completion of a residency or  
62.5 fellowship, is entitled to the continued privileges of internship registration.

62.6 [For text of subp 7, see M.R.]

## 62.7 **6800.5350 PRECEPTORS.**

62.8 Subpart 1. **Certificates.** Pharmacists intending to act as preceptors for  
62.9 pharmacist-interns ~~in licensed pharmacies shall first obtain preceptor certificates from~~

62.10 must register as preceptors with the board by submitting an application and any supporting  
 62.11 documentation required by the board. ~~Certificates~~ A preceptor registration shall be  
 62.12 renewed ~~expire~~ every other year on the anniversary of ~~their~~ its issuance. The board shall  
 62.13 grant ~~certificates~~ registrations or renewals to applicants who fulfill the requirements of  
 62.14 subparts 2 and 3.

62.15 Subp. 2. **Training and practice.** Applicants must show that:

62.16 A. they are participating in the ~~college-based externship~~ Experiential Education  
 62.17 Program of the University of Minnesota College of Pharmacy as an approved preceptor; or

62.18 B. they have completed at least 4,000 hours of ~~pharmacy practice after licensure~~  
 62.19 as a licensed pharmacist, with at least 2,000 hours of that ~~pharmacy practice after licensure~~  
 62.20 as a pharmacist in occurring within the state of Minnesota.

62.21 Subp. 3. **Other requirements.** In addition to fulfilling the requirements of subpart 2,  
 62.22 item A or B, applicants must show that:

62.23 [For text of items A and B, see M.R.]

62.24 C. they will provide time on at least a weekly basis for the purpose of helping  
 62.25 ~~the intern~~ their interns meet the competencies of the internship requirement; and

63.1 D. for renewal of a ~~certificate~~ registration only, that they have participated in an  
 63.2 instructional program specifically for preceptors, provided by or approved by the board,  
 63.3 within the previous 24 months.

63.4 **6800.5400 TRAINING.**

63.5 Subpart 1. **Intent.** The intent of this rule is to ~~provide~~ establish minimum standards  
 63.6 for the training of interns so that they are provided with a proper preceptor-intern  
 63.7 (teacher-student) relationship within the context of the employer-employee relationship,  
 63.8 provide and a broad base of internship practical experience, and supplement that

63.9 supplements didactic academic training in a manner which prepares ~~the intern~~ them for all  
63.10 aspects of the practice of pharmacy.

63.11 [For text of subp 2, see M.R.]

63.12 Subp. 3. **Training in other state.** When an intern desires to obtain credit for  
63.13 training received in a state other than Minnesota, the intern shall abide by the internship  
63.14 rules in that state, and shall provide evidence from that state's Board of Pharmacy ~~that~~  
63.15 ~~the intern's internship training has been completed in compliance with the internship~~  
63.16 ~~standards of the National Association of Boards of Pharmacy and with the standards~~  
63.17 ~~herein provided. Where a possible conflict may exist between the provisions of this part~~  
63.18 ~~and the requirements of the state in which the intern is training, the intern shall contact~~  
63.19 ~~the director of the Board of Pharmacy in Minnesota and outline any possible problem~~  
63.20 confirming completion of the number of internship hours for which credit is being  
63.21 requested. The board may deny requests for approval of credit for training received in  
63.22 a state other than Minnesota if the training does not meet the standards for internship  
63.23 described in this subpart.

63.24 Subp. 4. **Maximum trainees number of interns.** ~~No more than one intern shall be~~  
63.25 ~~trained by a preceptor at one time. A licensed pharmacist shall not be the preceptor for~~  
63.26 more than two interns at one time.

64.1 Subp. 4a. **Supervision: intern dispensing and compounding.** An intern  
64.2 performing tasks associated with dispensing or compounding shall be immediately and  
64.3 directly supervised by a licensed pharmacist stationed within the same work area who  
64.4 has the ability to control and is responsible for the actions of the intern. A licensed  
64.5 pharmacist may not supervise more than one intern who is performing tasks associated  
64.6 with dispensing or compounding. The ultimate responsibility for the actions of an intern  
64.7 performing tasks associated with dispensing or compounding shall remain with the  
64.8 licensed pharmacist who is supervising the intern.

64.9        Subp. 4b. **Supervision, generally.** Immediate and direct supervision by a licensed  
64.10 pharmacist is not required when an intern completes a medication history, gathers  
64.11 information for the purpose of formulating a pharmaceutical care plan or making a  
64.12 drug therapy recommendation, conducts educational activities for patients or staff,  
64.13 provides patient counseling, participates in patient rounds, or performs similar tasks that  
64.14 do not involve dispensing and compounding. However, all drug therapy and related  
64.15 recommendations that an intern proposes to make to other health professionals must  
64.16 be reviewed and approved by a licensed pharmacist before they are made. An intern's  
64.17 preceptor is responsible for the accuracy and completeness of statements made by the  
64.18 intern while providing counseling to patients or health-related education to patients or staff.

64.19        **Subp. 5. Competencies.** Upon registration, interns and preceptors will be furnished  
64.20 a copy of the board's internship manual, which lists the minimum competencies for that  
64.21 should be the focus of internship training. The competencies are furnished to suggest  
64.22 appropriate types and order of training experience and shall be used to ensure that the  
64.23 intern's practical experiences are commensurate with the intern's educational level, and  
64.24 broad in scope.

64.25        **Subp. 6. Evidence of completion.** Applicants for licensure as pharmacists who are  
64.26 examined and licensed after September 17, 1973, shall submit evidence that they have  
65.1 successfully completed not less than 1,500 hours of internship under the instruction and  
65.2 supervision of a preceptor. Effective May 1, 2003, candidates for licensure shall submit  
65.3 evidence that they have successfully completed not less than 1,600 hours of internship  
65.4 under the direction and supervision of a preceptor. Credit for internship shall be granted  
65.5 only to registered interns who have completed the third year of the five-year or six-year  
65.6 pharmacy curriculum, provided, however, that:

65.7            A. no more than 400 hours of concurrent time ~~internship credit may be acquired~~  
65.8 ~~by any combination of the following: internship experience gained concurrent with~~



65.9 attendance at a college of pharmacy during the fourth, fifth, and sixth year; participation  
65.10 in approved clinical pharmacy programs; or participation in approved internship  
65.11 demonstration projects such as industrial or research experiences will be granted to an  
65.12 intern;

65.13 B. ~~not more than 700 hours of internship credit may be given during any~~  
65.14 ~~internship segment; and~~

65.15 C B. ~~860 hours of internship credit may be acquired through Pharm D clinical~~  
65.16 ~~rotations on condition that the remaining 640 hours of the 1,500-hour total requirement is~~  
65.17 ~~of a traditional compounding, patient counseling, and dispensing nature. Effective May 1,~~  
65.18 ~~2003, 800 hours of internship credit may be acquired through Pharm D clinical rotations~~  
65.19 ~~on condition that experiential education program experiences that do not have as their~~  
65.20 ~~focus traditional compounding, dispensing, and related patient counseling activities. The~~  
65.21 ~~remaining 800 hours of the 1,600 hour total requirement is of a must focus on traditional~~  
65.22 ~~compounding, patient counseling, and dispensing nature, and related patient counseling~~  
65.23 ~~activities.~~

65.24 **6800.5500 RECIPROcity LICENSURE TRANSFER STANDARDS.**

65.25 The board may accept internship credit from applicants for licensure ~~by reciprocity~~  
65.26 ~~transfer~~ who have submitted evidence of completion of internship training in another  
66.1 state, provided that the training is, in the opinion of the board, substantially equivalent  
66.2 to the standards herein provided, and is in compliance with the internship standards of  
66.3 the National Association of Boards of Pharmacy, ~~and provided, further, that the applicant~~  
66.4 ~~has practiced pharmacy for one year prior to being examined for licensure in this state~~  
66.5 ~~pursuant to the requirements of part 6800.1300.~~

66.6 **6800.6200 PRESCRIPTION ORDER COMMUNICATION.**

66.7 Subpart 1. **Verbal or telephone orders.** Notwithstanding any other provisions  
66.8 of parts 6800.0100 to 6800.9700, a licensed pharmacist, registered nurse, or licensed

66.9 practical nurse who is employed by a licensed facility and who is authorized by the  
66.10 facility's administrator and is acting on the behalf of the prescriber, may communicate  
66.11 to the pharmacy provider a prescription drug order lawfully ordered by a practitioner  
66.12 authorized to prescribe drugs or devices pursuant to Minnesota Statutes, section 151.37.  
66.13 Whenever possible, these prescription drug orders shall be transmitted via facsimile or  
66.14 secure electronic format, to the pharmacy in an order format which produces a direct copy  
66.15 of the ~~prescription order as documented in the patient's chart~~ order, which the prescriber  
66.16 will sign at a later date. The pharmacy provider shall record on the prescription drug  
66.17 order the name of the person who transmits the order in addition to the other required  
66.18 information. This subpart does not apply to prescription drug orders for Schedule II  
66.19 controlled substances as defined by part 6800.4220.

66.20 Subp. 2. **Written orders.** A copy of a written prescription drug order, signed by  
66.21 the prescriber, ~~whether a chart order or a prescription~~, may be delivered to the pharmacy  
66.22 by an individual authorized by the facility.

66.23 Subp. 3. **Schedule II orders.** Except as provided in part 6800.3000, ~~subpart~~ subparts  
66.24 2 and 3, Schedule II controlled substances shall be dispensed only upon receipt of an  
66.25 original written prescription drug order manually signed by the prescribing individual  
67.1 practitioner or upon an oral order reduced to writing given in emergency situations as  
67.2 allowed by these criteria:

67.3 [For text of items A and B, see M.R.]

67.4 C. it is not reasonably possible for the prescribing practitioner to provide a  
67.5 written prescription drug order to be presented to the person dispensing the controlled  
67.6 substance, prior to dispensing.

67.7 **6800.6500 CONSULTING SERVICES TO LICENSED NURSING HOMES.**

67.8 [For text of subp 1, see M.R.]

67.9 Subp. 2. **Responsibilities.** The pharmacist shall be responsible for, but not limited  
67.10 to, the following:

67.11 [For text of items A to F, see M.R.]

67.12 G. providing in-service training to nursing personnel; ~~and~~

67.13 H. developing policies for the issuance of medications to residents who are  
67.14 going on leave from the facility. These policies may allow the preparation, by ~~facility~~  
67.15 ~~personnel~~ the facility's licensed or registered nurses responsible for overseeing medication  
67.16 administration, of a up to a 72-hour supply of medications, ~~not to exceed a 72-hour supply,~~  
67.17 in paper envelopes or other more suitable containers for use by a resident temporarily  
67.18 leaving the facility at times when the resident's pharmacy is closed or cannot supply the  
67.19 needed medication in a timely manner. A container may hold only one medication. A  
67.20 label on the container shall include the date, the resident's name, the facility, the name of  
67.21 the medication, its strength, dose, and time of administration, and the initials of the person  
67.22 preparing the medication and label; and

67.23 I. preparation of policies and procedures for the disposition of medications.

67.24 The policies and procedures must conform with the requirements of parts 4658.1350  
67.25 and 6800.2350.

68.1 Subp. 3. [See repealer.]

68.2 **6800.6700 DRUGS FOR USE IN EMERGENCY KITS.**

68.3 [For text of subp 1, see M.R.]

68.4 Subp. 2. **Emergency drug supplies.** Only emergency drug supplies determined  
68.5 by the quality assurance and assessment committee necessary for patient care in life  
68.6 threatening emergencies may be made available. The drugs in the emergency kit are the  
68.7 responsibility of the pharmacist and, therefore, shall not be used or altered in any way

68.8 except as outlined in this subpart. The emergency drug supplies shall comply with the  
68.9 following:

68.10 A. The drugs shall be limited to the extent possible to a 72-hour supply of any  
68.11 one emergency drug in either sealed ampules, vials, or prefilled syringes. If an emergency  
68.12 drug is not available in parenteral form, a supply in an alternate dosage form may be  
68.13 provided. Notwithstanding these restrictions, if the quality assurance and assessment  
68.14 committee considers it necessary, up to a 72-hour supply of each of a maximum of 15  
68.15 different oral pharmaceuticals, not counting oral antibiotics, restricted to therapeutic  
68.16 categories related to symptomatic patient distress or emergencies may be stocked. An  
68.17 unlimited number of oral antibiotics may be stocked in 72-hour supplies of each. Inclusion  
68.18 of other oral legend drugs is permissible only through the granting of a variance by the  
68.19 board. Drugs in the supply shall be properly labeled, including ~~expiration~~ beyond-use  
68.20 dates and lot numbers.

68.21 [For text of items B and C, see M.R.]

68.22 D. Drugs used from the kit shall be replaced by submitting a prescription drug  
68.23 order for the used item to the pharmacist within 72 hours and the supply shall be resealed  
68.24 by the pharmacist or the pharmacist's agent.

68.25 [For text of items E and F, see M.R.]

69.1 Subp. 3. **Controlled substances.** Emergency kits may contain limited supplies  
69.2 of controlled substances only if:

69.3 [For text of items A to F, see M.R.]

69.4 G. the controlled substances stored in the emergency kit are used only in a  
69.5 situation deemed an emergency by a licensed practitioner in conformity with the following  
69.6 provisions:

69.7 [For text of subitems (1) and (2), see M.R.]

69.8 (3) it is not reasonably possible for the prescribing practitioner to provide  
69.9 prior to administration a written prescription drug order to be presented to a pharmacist  
69.10 for dispensing of the controlled substance.

69.11 Subp. 4. **Excluded controlled substances.** Controlled substance ~~sedatives and~~  
69.12 stimulants in oral dosage forms may not be included in emergency kits.

69.13 [For text of subp 5, see M.R.]

69.14 **6800.7520 PHARMACEUTICAL SERVICE POLICIES.**

69.15 Subpart 1. **Dispensing drugs.** Pharmaceutical service policies shall cover at least the  
69.16 following measures related to the control, accessibility, dispensing, and administration  
69.17 of drugs:

69.18 [For text of items A to O, see M.R.]

69.19 P. Assuring that precautionary measures, including quality control  
69.20 documentation, for the safe admixture of parenteral products are developed in writing.  
69.21 Admixture preparation shall be limited to pharmacists, pharmacist-interns, supportive  
69.22 personnel under the supervision of a pharmacist, licensed practitioners, and licensed  
69.23 nurses. Furthermore, sterile admixtures shall be labeled as required in part 6800.7900;  
69.24 ~~subpart 4~~, and must be prepared ~~in a laminar or vertical flow hood whenever possible.~~  
70.1 ~~Chemotherapy admixtures shall be prepared in a vertical flow hood whenever possible~~  
70.2 as required in part 6800.3300, subpart 2.

70.3 [For text of items Q and R, see M.R.]

70.4 S. Developing, implementing, and maintaining a system of controlled substance  
70.5 and narcotic control in accordance with subitems (1) to (7).

70.6 (1) Controlled substances must be accounted for by either:

70.7 (a) a "proof-of-use" sign-out sheet where each dose given is accounted  
70.8 for by the ~~nurse administering~~ licensed health care professional who procures the drug.

70.9 No controlled substance may be kept on floor stock unless it is accompanied by the  
70.10 sign-out sheet and each dose is documented by the ~~nurse~~ licensed health care professional  
70.11 at the time the drug is procured from the ~~nursing station~~ stock. The proof-of-use sheets  
70.12 must include at least the date and time, the patient's name, the dose administered, and the  
70.13 licensed ~~nurse's~~ health care professional's signature; ~~or~~

70.14 (b) the dispensing of the drug to a specific patient after the pharmacy  
70.15 receives an individual drug order; or

70.16 (c) a computer system which utilizes electronic distribution records  
70.17 of controlled substance transactions as long as the system complies with the following  
70.18 requirements:

70.19 i. allows for retrieval of all information required by this regulation  
70.20 for all distribution and dispensing transactions for two years;

70.21 ii. provides for at least weekly transaction printouts, except that  
70.22 this requirement does not have to be met if a secure daily 24-hour backup is performed  
70.23 which allows for restoration of required information in case of a system failure;

71.1 iii. maintains a complete online transaction file that is printable  
71.2 on request, or have a "lock-out" feature that prevents editing of distribution or dispensing  
71.3 information;

71.4 iv. allows for the printing of a report of all distribution and  
71.5 dispensing transactions for a minimum of two years. The system must be capable of  
71.6 retrieving and printing a report listing variables which include, but are not limited to:  
71.7 the identity of a user accessing the system; the date and time controlled substances are  
71.8 distributed to or removed from the automated distribution machine; the quantity of a  
71.9 controlled substance distributed to or removed from the automated distribution machine;  
71.10 drug name, strength, and dosage form; patient name; and practitioner name.

71.11 (2) ~~Wasted~~ Wasting of doses must be documented and witnessed carried  
71.12 out by the signature of two licensed individuals who are nurses or pharmacists, authorized  
71.13 to have access to controlled substances. The wasting of doses must be documented, with  
71.14 the accuracy of the documentation being certified by the licensed individuals who carried  
71.15 out the wasting. Certification must include the signature or other unique identifier of the  
71.16 licensed individuals who carried out the wasting.

71.17 (3) There must be a system for reconciling the proof-of-use sheets in the  
71.18 pharmacy to assure accountability of all sheets sent to the various nursing stations.

71.19 (4) Controlled substances must be stored under lock on the nursing stations  
71.20 or other patient care area.

71.21 [For text of subitems (5) to (7), see M.R.]

71.22 T. Developing policies for the issuance of medications to patients who are going  
71.23 on leave from the facility. These policies may allow the preparation, by ~~facility personnel~~  
71.24 the facility's registered nurses responsible for overseeing medication administration, of a  
71.25 supply of medications, not to exceed a 72-hour supply, in paper envelopes or other more  
71.26 suitable containers for use by a patient temporarily leaving the facility at times when the  
72.1 facility's pharmacy is closed or cannot supply the needed medication in a timely manner.  
72.2 A container may hold only one medication. A label on the container shall include the date,  
72.3 the patient's name, the facility, the name of the medication, its strength, dose, and time of  
72.4 administration, and the initials of the person preparing the medication and label.

72.5 [For text of subp 2, see M.R.]

72.6 **6800.7900 PRESCRIPTION LABELING.**

72.7 Subpart 1. **Outpatient prescriptions.** Labels for filled outpatient prescriptions  
72.8 prescription drug orders shall comply with parts 6800.3400 and 6800.4150. Labels  
72.9 for outpatient nonprescription drugs shall comply with the federal regulations. Drugs

72.10 originally dispensed to an inpatient shall be returned to the pharmacy for proper labeling  
72.11 before leaving the hospital premises.

72.12 Subp. 2. **Inpatient ~~prescriptions~~ chart orders.** The containers of all prescriptions  
72.13 drugs dispensed to inpatients on the basis of chart orders, other than those dispensed  
72.14 pursuant to part 6800.3750, shall be labeled with the following information:

72.15 [For text of items A to G, see M.R.]

72.16 [For text of subps 3 and 4, see M.R.]

72.17 Subp. 5. **Intravenous admixtures.** Intravenous admixtures must be labeled with  
72.18 the following information:

72.19 A. name of solution, ~~lot number~~, and volume of solution;

72.20 [For text of items B to F, see M.R.]

72.21 ~~G. identity of the pharmacist preparing or certifying the admixture;~~

72.22 ~~H G.~~ date and time of administration if appropriate;

72.23 ~~I H.~~ expiration beyond-use date and date and time of compounding; and

72.24 ~~J I.~~ ancillary precaution labels.

73.1 Subp. 6. **Responsibility.** The hospital pharmacy service is responsible for ensuring  
73.2 proper labeling of all medications.

73.3 **6800.8000 SCOPE AND PURPOSE.**

73.4 The purpose of parts 6800.8000 to 6800.8008 is to provide standards  
73.5 for the preparation, labeling, and distribution of sterile products by licensed  
73.6 ~~parenteral-enteral/home~~ home health care pharmacies pursuant to ~~an order or a~~ a prescription  
73.7 drug order. The standards are intended to apply to sterile products compounded by the  
73.8 pharmacist, notwithstanding the location of the patient, such as a private home, nursing  
73.9 home, hospice, or doctor's office.



73.10 **6800.8004 DRUG DISTRIBUTION AND CONTROL.**

73.11 Subpart 1. **General.** This part governs the mechanism by which a ~~physician's~~  
73.12 practitioner's prescription drug order is executed, from the time the drug is ordered and  
73.13 received in the pharmacy to the time the prescribed drug is dispensed to the patient.

73.14 Subp. 2. **Prescription.** The pharmacist, or pharmacist-intern acting under the  
73.15 immediate supervision of a pharmacist, must receive a ~~written or oral~~ prescription drug  
73.16 order from a ~~physician~~ practitioner before dispensing any compounded, sterile parenteral  
73.17 product. Prescriptions must be filed as required by law or rules of the board.

73.18 Subp. 3. **Labeling.** Each compounded intravenous admixture product must be  
73.19 labeled in accordance with part 6800.3450.

73.20 Subp. 4. **Delivery.** The pharmacist-in-charge shall ~~assure~~ ensure the environmental  
73.21 control of all products shipped as follows:

73.22 A. compounded, sterile pharmaceuticals must be shipped or delivered to a  
73.23 ~~patient in appropriate temperature-controlled delivery containers, as defined by United~~  
73.24 ~~States Pharmacopoeia standards, as required in part 6800.3000~~ and stored appropriately in  
73.25 the patient's home; and

74.1 B. chain of possession for the delivery of Schedule II controlled substances via  
74.2 courier must be documented, and a receipt obtained.

74.3 **6800.8007 PATIENT CARE GUIDELINES.**

74.4 Subpart 1. **Primary provider.** The pharmacist who assumes the responsibilities  
74.5 under this part must ensure that there is a designated ~~physician~~ practitioner primarily  
74.6 responsible for the patient's medical care and that there is a clear understanding between the  
74.7 ~~physician~~ practitioner, licensed home care agency, if any, the patient, and the pharmacist  
74.8 of the responsibilities of each in the areas of the delivery of care and the monitoring of the  
74.9 patient. Compliance with this subpart shall be documented in the patient's profile.

74.10 [For text of subp 2, see M.R.]

74.11 Subp. 3. **Patient monitoring.** The pharmacist shall request access to clinical and  
74.12 laboratory data concerning each patient and, if the data is obtained, monitor each patient's  
74.13 response to drug therapy. Any unexpected or untoward response shall be reported to  
74.14 the prescribing physician practitioner. If the data is not obtained and the pharmacist is  
74.15 not doing the monitoring, the identity of the health care provider who has assumed the  
74.16 responsibility shall be documented in the patient's profile.

74.17 Subp. 4. **Emergency kit.** The pharmacy may provide emergency medications and  
74.18 supplies to be used by designated, registered nurses, employed in the hospice or home  
74.19 health care setting.

74.20 The minimum requirements relating to the establishment of an emergency kit are  
74.21 described in items A to C.

74.22 [For text of item A, see M.R.]

74.23 B. Appropriate and agreed-to policies and procedures for the use of the kit must  
74.24 be developed by hospice and home health agencies in conjunction with the supplying  
75.1 pharmacy. Copies of the policies and procedures must be kept at the supplying pharmacy  
75.2 and a copy submitted to the board. The policies and procedures must address the following:

75.3 [For text of subitems (1) to (4), see M.R.]

75.4 (5) the method by which a pharmacy would be furnished with a copy of  
75.5 each prescriber's prescription drug order or approved protocol reference which will be  
75.6 used as a hard copy prescription drug order and will trigger drug replacement; and

75.7 [For text of subitem (6), see M.R.]

75.8 [For text of item C, see M.R.]

75.9 **6800.8550 LABELING OF RADIOPHARMACEUTICALS.**

75.10 **Subpart 1. Immediate container of bulk radiopharmaceutical product.** Each  
75.11 **compounded container must bear a label containing the following information:**

75.12 **A. standard radiation symbol with words "Caution - Radioactive Material";**

75.13 **B. radiopharmaceutical name or its abbreviation; and**

75.14 **C. radiopharmaceutical lot number.**

75.15 **Subp. 2. Outer container of bulk radiopharmaceutical product.** Each individual  
75.16 **prepared dose must bear a label containing the following information:**

75.17 **A. standard radiation symbol with words "Caution - Radioactive Material";**

75.18 **B. radiopharmaceutical name or its abbreviation;**

75.19 **C. amount of radioactivity;**

75.20 **D. calibration date and time;**

75.21 **E. expiration date and time;**

75.22 **F. volume - if liquid, weight - if solid, number of vials or ampoules - if gas,**  
75.23 **number of capsules - if capsules;**

76.1 **G. added substances, such as stabilizers and preservatives;**

76.2 **H. radiopharmaceutical lot number;**

76.3 **I. name, address, and telephone number of nuclear pharmacy, if it is to be**  
76.4 **transferred for commercial distribution; and**

76.5 **J. initials of preparing nuclear pharmacist, if it is to be transferred for**  
76.6 **commercial distribution.**

76.7 **Subp. 3. Immediate container of each radiopharmaceutical dispensed.** Each  
76.8 **individual prepared dose must bear a label containing the:**

76.9 A. standard radiation symbol with words "Caution - Radioactive Material";

76.10 B. radiopharmaceutical name or its abbreviation;

76.11 C. radiopharmaceutical prescription or lot number; and

76.12 D. patient name.

76.13 **Subp. 4. Outer container of each radiopharmaceutical dispensed. Each**

76.14 **individual prepared dose must bear a label containing the:**

76.15 A. standard radiation symbol with words "Caution - Radioactive Material";

76.16 B. radiopharmaceutical name or its abbreviation;

76.17 C. amount of radioactivity;

76.18 D. calibration date and time;

76.19 E. expiration date and time;

76.20 F. volume - if liquid, or weight - if solid, and number of vials or ampoules -

76.21 if gas;

76.22 G. added substances, such as stabilizers and preservatives;

76.23 H. radiopharmaceutical prescription or lot number;

77.1 I. name, address, and telephone number of nuclear pharmacy;

77.2 J. patient name; and

77.3 K. initials of dispensing nuclear pharmacist.

77.4 **6800.9900 VARIANCES.**

77.5 [For text of subps 1 to 4, see M.R.]

77.6 **Subp. 5. Renewal of variance.** Any request for the renewal of a variance shall be

77.7 submitted in writing prior to the expiration date of the existing waiver. Renewal requests

77.8 shall contain the information specified in subpart 2. A variance shall be renewed by

77.9 the board if the applicant continues to satisfy the criteria contained in subpart 3 and  
77.10 demonstrates compliance with the alternative measures or conditions imposed at the time  
77.11 the original variance was granted.

77.12 Subp. 5a. **Successor pharmacist-in-charge duties for active variances.** After  
77.13 termination of the services of a pharmacist-in-charge, the successor pharmacist-in-charge  
77.14 shall submit, on the approved form, an acknowledgment of an awareness and  
77.15 understanding of any active variances that the pharmacy has been granted according  
77.16 to this part. The successor pharmacist-in-charge shall be responsible for ensuring  
77.17 that any conditions imposed by the board on any active variances continue to be met.  
77.18 Existing active variances shall remain in effect until the successor pharmacist-in-charge  
77.19 successfully submits the forms required in this subpart, for 90 days from the naming of  
77.20 a successor pharmacist-in-charge, or until the expiration date of the existing variance,  
77.21 whichever is sooner.

77.22 [For text of subp 6, see M.R.]

77.23 **6800.9921 REGISTRATION.**

77.24 [For text of subp 1, see M.R.]

78.1 Subp. 2. **Issuance.** Upon the filing of an application for registration, and upon the  
78.2 payment of a the applicable fee of \$50 in chapter 151, the board shall issue a registration  
78.3 certificate in a form it prescribes. An application for a medical gas distributor registration  
78.4 which has not been completed within 12 months of the date on which the board received  
78.5 the application is no longer valid.

78.6 [For text of subps 3 and 4, see M.R.]

78.7 **REPEALER.** Minnesota Rules, parts 6800.0100, subpart 2a; 6800.1300, subpart 6;  
78.8 6800.3110, subpart 6; 6800.5100, subparts 1, 7, 8, 9, and 10; 6800.5300, subpart 4; and  
78.9 6800.6500, subpart 3, are repealed.